REMERCIEMENTS

Je remercie mon directeur de recherche, D^r France Varin, pour ses directives et conseils judicieux et pour la patience dont elle a fait preuve à mon égard tout au long de mes travaux.

De plus, je tiens également à remercier mon codirecteur de recherche, D^r Christine Des Rosiers, pour sa contribution importante qui m'a permis d'élargir la dimension de mon projet ainsi que pour sa rigueur scientifique.

Je remercie Novartis Pharma Canada Inc. et le CRM pour leur aide financière. J'aimerais exprimer ma gratitude à The Minh Tu, Johanne Couture, Bertrand Bouchard, Julie Pelletier et Elise Donnedieu pour leur aide technique.

Remerciements aux personnes suivantes :

• tous mes collègues au laboratoire du D^r Varin à l'Université de Montréal, de même qu'à mes collègues du laboratoire de métabolisme intermédiaire du pavillon Notre-Dame du Centre Hospitalier de l'Université de Montréal;
• mes collègues chez Novartis Pharma Canada (plus spécialement aux services de documentation); et
• des remerciements particuliers à Lise Martin pour ses excellentes révisions éditoriales et à Lisa Putnam pour son soutien administratif inestimable tout au long de mon projet.

Enfin, je tiens à remercier vivement ma conjointe, Stéphanie, pour son soutien qui m'a été si précieux et qui m'a permis de mener à terme ce projet de doctorat.

Bibliographie

• Åberg F, Appelkvist EL, Broijersen A, Eriksson M, Angelin B, Hjemdahl P, Dallner G: Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gamma-tocopherol levels in men with combined hyperlipidemia. Eur J Clin Invest 1998, 28(3): 235-242
• Åberg F, Appelkvist EL, Dallner G, Ernster L: Distribution and redox state of ubiquinones in rat and human tissues. Arch Biochem Biophys 1992, 295(2): 230-234
• Alary J, Debrauwer L, Fernandez Y, Cravedi JP, Rao D, Bories G: 1,4-Dihydroxynonene mercapturic acid, the major end metabolite of exogenous 4-hydroxy-2-nonenal, is a physiological component of rat and human urine. Chem Res Toxicol 1998, 11: 130-135
• Alesssandri MG, Scalori V, Giovannini L, Mian M, Bertelli AA: Plasma and tissue concentrations of coenzyme Q₁₀ in the rat after intravenous administration by a microsphere delivery system or in a new type of solution. Int J Tissue React 1988, 10(2): 99-102
• Alleva R, Tomasetti M, Bompadre S, Littaru GP: Oxidation of LDL and their subfractions: kinetic aspects and CoQ₁₀ content. Molec Aspects Med, 1997, 18(suppl): S105-S112
• Ambrosio G, Santoro G, Tritto I, Elia PP, Duilio C, Basso A, Scognamiglio A, Chiariello M: Effects of ischemia and reperfusion on cardiac tolerance to oxidative stress. Am J Physiol 1992, 262: H23-H30
• Ames BN, Cathcart R, Schwiers E, Hochstein P: Uric acid provides an antioxidant defense in humans against oxidant and radical caused aging and cancer : A hypothesis. Proc Natl Acad Sci (USA) 1981, 78: 6858-6862
• Amin D, Gustafson S, Perrone MH: Lovastatin is hypertriglyceridemic in Syrian golden hamsters. Biochem Biophys Res Commun 1988, 157(2): 530-534
• Amin D, Rutledge RZ, Needle SN, Galczenski HF, Neuenschwander K, Scotese AC, Maguire MP, Bush RC, Hele DJ, Bilder GE, Perrone MH: RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. J Pharmacol Exp Ther 1997, 281(2): 746-752
• Andersson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P: The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. NEJM 1995, 332: 488-493
• Ansari NH, Wang L, Srivastava SK: Role of lipid aldehydes in cataractogenesis: 4-hydroxynonenal-induced cataract. Biochem Mol Med 1996, 58 (1): 25-30 Appelkvist EL, Edllund C, Löw P, Schedin S, Kalén A, Dallner G: Effects of inhibitors of hydroxymethylglutaryl coenzyme A reductase on coenzyme Q and dolichol biosynthesis. Clin Investig, 1993, 71(8 suppl): S97-S102
• Artuch R, Vilaseca MA, Pineda M: Biochemical monitoring of the treatment in paediatric patients with mitochondrial disease. J Inherit Metab Dis, 1998, 21(8): 837-845
• Austin MA, Hokanson JE, Brunzell JD: Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol 1994, 5: 395-403
• Aviram M: Platelet secretory products enhance LDL receptor activity and inhibit scavenger receptor activity in human monocyte-derived macrophage. Metabolism 1989, 38: 425-430
• Aviram M, Brook JG: Platelet enhancement of macrophage cholesterol accumulation: a novel mechanism for atherogenesis, pp. 67-71, in: Halpern MJ (ed) Molecular biology of atherosclerosis                of the 57th European Atherosclesrosis Society Meeting, London 1997
• Aviram M, Damkner G, Cogan U, Hochgraf E, Brook JG: Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies. Metabolism 1992, 3: 229-235
• Aviram M, Hussein O, Rosenblat M, Schlesinger S, Hayek T, Keidar S: Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardiovasc Pharmacol 1998a, 31: 39-45
• Aviram M, Rosenblat M, Bisgaier CL, Newton RS: Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998b, 138: 271-280
• Baggio E, Gandini R, Plancher AC, Passeri M, Carmosino G: Italian multicenter study on the safety and efficacy of coenzyme Q₁₀ as adjunctive therapy in heart failure. Mol Aspects Med 1994, 15(suppl): 287-294
• Balasubramanian S, Szanto A, Roach PD: Circadian rythm in hepatic low-density-lipoprotein (LDL) receptor expression and plasma LDL levels. Biochem J 1994, 298: 39-43
• Bankson DD, Kestin M, Rifai N: Role of free radicals in cancer and atherosclerosis. Clin Lab Med 1993, 13(2): 463-480
• Bantle JP: TSH response to TRH in euthroid hypercholesterolemic patients treated with graded doses of dextrothyroxine. Metabolism 1981, 30: 63-68
• Barclay LRC, Locke SJ, MacNeil JM: The autoxidation of unsaturated lipids in micelles. Synergism of inhibitors vitamin C and E. Can J Chem 1983, 61: 1288-1290
• Bargossi AM, Grossi G, Fiorella L, Gaddi A, Di Giulio, Battino M: Exogenous CoQ₁₀ supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. Mol Aspects Med 1994, 15(suppl):s187-S193
• Barrera G, Martinotti S, Fazio V, Manzari V, Paradisi L, Parola M, Frati L, Dianzani MU: Inhibition of the expression of the c-myc oncogene in K 562 cells. Toxicol Pathol 1987, 15: 238-240
• Baxter A, Fitzgerald BJ, Hutson JL, McCarthy AD, Moteram JM, Ross BC, Sapra M, Snowden MA, Watson NS, Williams RJ, Wright C: Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo. J Biol Chem 1992, 267(17): 11705-11708
• Bélichard P, Pruneau D, Zhiri A: Effect of a long-term treatment with lovastatin or fenobibrate on hepatic and cardiac ubiquinone levels in cardiomyopathic hamster. Biochim Biophys Acta 1993, 1169: 98-102
• Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L, Fumagalli R, Paoletti R, Corsini A: Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998, 137(suppl): S101-S109
• Belo RS, Jamieson JC, Wright JA: Studies on the effect of mevinolin (lovastatin) and mevastatin (compactin) on the fusion of L6 myoblasts. Mol Cell Biochem 1993, 126: 159-167
• Benedetti A, Barbieri L, Ferrali M, Casini AF, Fulceri R, Comporti M: Inhibition of protein synthesis by carbonyl compounds (4-hydroxyalkenals) originating from the peroxidation of liver microsomal lipids. Chem Biol Interact 1981, 35: 331-340
• Benedetti A, Casini AF, Ferrali M, Comporti M: Effects of diffusible products of peroxidation of rat liver microsomal lipids. Biochem J 1979, 180: 303-312
• Benedetti A, Comporti M, Esterbauer H: Identification of 4-hydroxynonenal as a cytotoxic product originating from the peroxidation of liver microsomal lipids. Biochim Biophys Acta 1980, 620: 281-296
• Benedetti A, Comporti M, Fulceri R, Esterbauer H: Cytotoxic aldehydes originating from the peroxidation of liver microsomal lipids. Identification of 4,5-dihydroxydecenal. Biochim Biophys Acta 1984a, 792: 172-181
• Benedetti A, Fulceri R, Comporti M: Inhibition of calcium sequestration activity of liver microsomes by 4-hydroxyalkenals originating from the peroxidation of liver microsomal lipids. Biochim Biophys Acta 1984b, 793: 489-493
• Berglund LF, Beltz WF, Elam RL, Witztum, JL: Altered apolipoprotein B metabolism in very low density lipoprotein from lovastatin-treated guinea pigs. J Lipid Res 1994, 35: 956-965
• Betteridge DJ: Cholesterol lowering and secondary prevention of CHD - the evidence of benefit is unequivocal, Ch.16, pp.261-271, in: Betteridge DJ (ed): Lipids: Current Perspectives. Martin Duuitz Ltd., London 1996
• Beyer RE: The role of ascorbate in antioxidant protection of biomembranes: Interaction with vitamin E and coenzyme Q. J Bioenerg Biomembr 1994, 26(4): 349-358
• Beyer RE, Ernster L: The antioxidant role of coenzyme Q, pp. 191-213 in: Lenaz G, Barnabei O, Batti A, Battino M (eds): Highlights in ubiquinone research. Taylor & Francis, London 1990
• Beyer RE, Nordenbrand K, Ernster L: The function of coenzyme Q in free radical production and as an antioxidant: A Review. Chemica Scripta 1987, 27: 145-154
• Beyer RE, Nordenbrand K, Ernster L: The role of coenzyme Q as a mitochondrial antioxidant: a short review, pp. 17-24 in: Biomedical & Clinical Aspects of Coenzyme Q. 1986 Vol. 5
• Beyer RE, Segura-Aquilar J, Di Bernardo S, Cavazzoni M, Fato R, Fiorentini D, Galli MC, Setti M, Landi L, Lenaz G: The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc Natl Acad Sci (USA) 1996, 93 (March): 2528-2532
• Beyer RE, Segura-Aquilar J, Di Bernardo S, Cavazzoni M, Fato R, Fiorentini D, Galli MC, Setti M, Landi L, Lenaz G: The two-electron quinone reductase DT-diaphorase generates and maintains the antioxidant (reduced) form of coenzyme Q in membranes. Molec Aspects Med 1997, 18(suppl): S15-S23
• Biaglow JE: Role of glutathione and other thiols in cellular response to radiation and drugs. Drug Metab Rev 1989, 20: 1-12
• Bickis IJ, Schauenstein E, Taufer M: Effects of hydroxypentenal on the metabolism of tumor cells and normal cells. Monatsh Chem 1968, 100: 1077-1104
• Bielski B, Richter H: Some properties of the ascorbate free radical. Ann NY Acad Sci (USA) 1975, 258: 231-237
• Bjelajac A, Goo AKY, Weart CW: Prevention and regression of atherosclerosis: effects of HMG-CoA reductase inhibitors. Ann Pharmacother 1996, 30(11): 1304-1315
• Björkhem I: Mechanism of degradation of the steroid side chain in the formation of bile acids. J Lipid Res 1992, 33: 455-471
• Blanc EM, Kelly JF, Mark RJ, Waeg G, Mattson MP: 4-Hydroxynonenal, an aldehydic product of lipid peroxidation, impairs signal transduction associated with muscarinic acetylcholine and metabotropic glutamate receptors: possible action on G alpha(q/11). J Neurochem 1997, 69(2): 570-580
• Blasig IE, Grune T, Schonheit K, Rohde E, Jakstadt M, Haselhoff RF, Siems WG: 4-Hydoxynonenal, a novel indicator of lipid peroxidation for reperfusion injury of the myocardium. Am J Physiol 1995, 269(1 PT 2): H14-H22
• Blasig IE, Sporbert A, Utepbergenov DI, Schroeter ML, Mertsch K, Haseloff RF: Cytokine- and hypoxia-induced lipid peroxidation in astrocytes. Int J Clin Pharmacol Ther 1998, 36(2): 112-113
• Bliznakov EG, Wilkins DJ: Biochemical and clinical consequences of inhibiting coenzyme Q₁₀ biosynthesis by lipid-lowering HMG-CoA reductase inhibitors (statins): A critical overview. Adv Ther 1998, 15(4): 218-228
• Bocan ThMA, Ferguson E, McNally W, Uhlendorf PD, Bak-Mueller S, Dehart P, Sliskovic DR, Roth BD, Krause BR, Newton RS: Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors. Biochim Biophys Acta 1992, 1123: 133-144
• Bochaton Piallar ML, Gabbiani F, Redard M, Desmoulière A, Gabbiani G: Apoptosis participates in cellularity regulation during rat aortic intimal thickening. Am J Pathol 1995, 146: 1059-1064
• Böger RH, Bode-Böger SM, Brandes RP, Phivthong-ngam L, Böhme M, Nafe R, Mügge A, Frölich JC: Dietary l-arginine reduces the progression of atherosclerosis on cholesterol-fed rabbits. Circulation 1997, 96: 1282-1290
• Bondy SC, Naderi S: Contribution of hepatic cytochrome P450 systems to the generation of reactive oxygen species. Biochem Pharmacol 1994, 48: 155-159
• Bowry VW, Ingold KU, Stocker R: Vitamin E in human low-density lipoprotein. When and how this antioxidant becomes a pro-oxidant. Biochem J 1992b, 288(2): 341-344
• Bowry VW, Mohr D, Cleary J, Stocker R: Prevention of tocopherol-mediated
• peroxidation
• in ubiquinol-10-free human low density lipoprotein. J Biol Chem 1995, 270(11): 5756-5763
• Bowry VW, Stocker R: Tocopherol-mediated peroxidation. The pro-oxidant effect of vitamin E on the radical-initiated oxidation of human low-density lipoprotein. J Am Chem Soc 1993, 115: 6029-6040
• Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J, Hurley DP, Langendorfer A, Nash DT, Pool JL, Schnaper H: Expanded clinical evaluation of lovastatin (EXCEL) study results.I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med, 1991, 151: 43-49
• Brambilla G, Sciaba L, Faggin P, Maura A, Marinari UM, Ferro M, Esterbauer H: Cytotoxicity, DNA fragmentation and sister-chromatid exchange in chinese hamster ovary cells exposed to the lipid peroxidation product 4-hydroxynonenal and homologous aldehydes. Mutation Res 1986, 171: 169-176
• Brennan RJ, Swoboda BE, Sciesti RH: Oxidative mutagens induce intrachromosomal recombination in yeast. Mutal Res 1994, 308: 159-167
• Brown ML, Hesler C, Tall AR: Plasma enzymes and transfer proteins in cholesterol metabolism. Curr Opin Lipidol 1990, 1: 122-127
• Brown MS, Goldstein JL: Multivalent feedback regulation of HMG-CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 1980, 21: 505-517
• Brown MS, Goldstein JL: Drugs used in the treatment of hyperlipoproteinemias, Chapter 34, pp. 827-845 in: Goodman and Gillman 1990 8th edition
• Brown MS, Goldstein JL: A receptor-mediated pathway for cholesterol homeostasis. Science 1981, 232 (4.04): 34-47
• Brown MS, Goldstein JL: How LDL receptors influence cholesterol and atherosclerosis, pp. 100-108, in: The Laureates' anthology Vol. II. A collection of articles by Nobel Prize-Winning authors. (Sci Am) 1991 pp.58-66
• Bruckert E, Giral P, Dairou F, De Gennes JL: Lipoprotéines de haute densité-cholestérol: métabolisme et rôle dans l'athérosclérose. Presse Méd 1988, 17(17): 862 - 866
• Buettner GR: The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch Biochem Biophys 1993, 300(2): 535-543
• Burton GW, Ingold KU: b-carotene: an unusual type of lipid antioxidant. Science 1984, 224: 569-573
• Burton GW, Joyce A, Ingold KU: First proof that vitamin E is a major lipid-soluble, chain-breaking antioxidant in human blood plasma. Lancet 1982, 1: 327
• Burton GW, Webb A, Ingold KU: A mild, rapid, and efficient method of lipid extraction for use in determining vitamin E/lipid ratios. Lipids 1985, 20(1): 29-39
• Cadenas E, Müller A, Brigelius R, Esterbauer H, Sies H: Effects of 4-hydroxynonenal on isolated hepatocytes. Biochem J 1983, 214: 479-487
• Cajelli E, Ferraris A, Brambilla G: Mutagenicity of 4-hydroxynonenal in V79 Chinese hamster lung cells. Mutation Res 1984, 44: 169-171
• Cajone F, Bernelli-Zazzera A: Oxidative stress induces a subset of heat shock proteins in rat hepatocytes and MH1C1 cells. Chem Biol Interact 1988, 65: 235-246
• Cajone F, Bernelli-Zazzera A: The action of 4-hydroxynonenal on heat shock gene expression in cultured hepatoma cells. Free Rad Res Commun 1989, 7: 189-194
• Cajone F, Salina M, Benelli-Zazzera A: 4-Hydroxynonenal induces a DNA-binding protein similar to the heat-shock factor. Biochem J 1989, 262: 977-979
• Cambiaggi C, Dominici S, Comporti M, Pompella A. Modulation of human T lymphocyte proliferation by 4 hydroxynonenal, the bioactive product of neutrophil dependent lipid peroxidation. Life Sci 1997, 61(8): 777-785
• Carini R, Bellomo G, Paradisi L, Dianzani M U, Albano E: 4-hydroxynonenal triggers Ca2+ influx in isolated rat hepatocytes. Biochem Biophys Res Commun 1996, 218(3): 772-776
• Castelli WP: The triglyceride issue: A view from Framingham. Am Heart J 1986, 112: 432-437
• Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB: Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framigham Study JAMA 1986, 256(20): 2835-2838
• Castilho RF, Kowaltowski AJ, Meinicke AR, Vercesi AE: Oxidative damage of mitochondria induced by Fe(II)citrate or t-butyl hydroperoxide in the presence of CA²⁺: Effect of coenzyme Q redox state. Free Rad Biol Med 1995, 18(1): 55-59
• Cavallini L, Valente M, Bindoli A: Comparison of cumene hydroperoxide- and NADPH/Fesup 3Sup+/ ADP- induced lipid peroxidation in heart and liver submitochondrial particles. Mechanisms of protection by succinate. Biochim Biophys Acta 1984, 795: 466-472
• Cendella RJ: Cholesterol and cataracts. Surv Ophthalmol 1996, 40: 320-337
• Chello M, Mastroroberto P, Romano R, Bevacqua E, Pantaleo D, Ascione R, Marchese AR, Spampinato N: Protection by coenzyme Q₁₀ from myocardial reperfusion injury during coronary artery bypass grafting. Ann Thorac Surg 1994, 58: 1427-1432
• Chello M, Mastroroberto P, Romano R, Castaldo P, Bevacqua E, Marchese AR: Protection by coenzyme Q₁₀ of tissue reperfusion injury during abdominal aortic cross-clamping. J Cardiovasc Surg 1996, 37: 229-235
• Chen Q, Esterbauer H, Jürgens G: Studies on epitopes on low density lipoprotein modified by 4-hydroxynonenal. Biochemical characterization and determination. Biochem J 1992, 288(Pt 1): 249-254
• Chen J, Schenker S, Frosto TA, Henderson GI: Inhibition of cytochrome c oxidase activity by 4-hydroxynonenal (HNE). Role of HNE adduct formation with the enzyme subunits. Biochim Biophys Acta 1998, 1380(3): 336-344
• Chopra RK, Goldman R, Sinatra ST, Bhagavan HN: Relative bioavailability of coenzyme Q₁₀ formulations in human subjects. Int J Vitam Nutr Res 1998, 68(2): 109-113
• Chylack LT Jr, Mantell G, Wolfe JK, Friend J, Rosner B, Baker M, Grabowski R, Herzberg S, Jakubicz G, Khu P, Libman J, McCarthy D, McDonald B, Padhye N, Wehner C, Lippa E, Gould L, Staggers J: The MSDRL Study Group. Lovastatin and human lens; results of a two year study. Optom Vision Sci 1993, 70: 937-943
• Clark IA, Butcher GA, Buffinton GD, Hunt N, Cowden WB: Toxicity of certain products of lipid peroxidation to the human malaria parasite plasmodium falciparum. Biochem Pharmacol 1987, 38: 543-546
• Comporti M: Lipid peroxidation and biogenic aldehydes: From the identification of 4-hydroxynonenal to further achievements in biopathology. Free Rad Res 1998, 28(6): 623-635
• Comporti M: Lipid peroxidation and cellular damage in toxic liver injury. Lab Invest 1985, 53(6): 599-623
• Comporti M: Three models of free radical-induced cell injury. Cell Biol Interact 1989, 72: 1-56
• Corpier CL, Jones PH, Suki WN, Lederer ED, Quinones MA, Schmidt ShW, Young JB: Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA 1988, 260(2): 239-241
• Corsini A, Mazzotti M, Raiteri M, Soma MR, Gabbiani G, Fumagalli R, Paoletti R: Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993, 101: 117-125
• Corsini A, Pazzucconi F, Arnaboldi L, Pfister P, Fumagalli R, Paoletti R, Sirtori CR: Direct effects of statins on the vascular wall. J Cardiovas Pharmacol 1998, 31: 773-778
• Corsini A, Pazzucconi F, Pfister P, Paoletti R, Sirtori CR: Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin. Lancet 1996, 348 ( Dec.7): 1584
• Corsini A, Raiteri M, Soma MR, Bernini F, Fumagalli R, Paoletti R: Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Am J Cardiol 1995, 76: 21A-28A
• Crane FL: Physiological coenzyme Q function and pharmacological reactions, pp. 3-14 in: Folkers K, Yamamura Y (eds): Biomedical and clinical aspects of coenzyme Q., Vol. 5, 1986
• Crane FL, Sun IL, Sun EE: The essential functions of coenzyme Q. Clin Investig 1993, 71: S55-S59
• Crouse III JR, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD: Pravastatin, lipids, and atherosclerosis in carotid arteries (PLAC II). Am J Cardiol 1995, 75: 455-459
• Curzio M: Interaction between neutrophils and 4-hydroxyalkenals and consequences on neutrophil motility. Free Rad Res Comms 1988, 5: 55-66
• Curzio M, Esterbauer H, Dianzani MU: Chemotactic activity of hydroxyalkenals on rat neutrophils. Int J Tissue React 1985, 7: 137-142
• Curzio M, Esterbauer H, Di Mauro C, Cecchini G, Dianzani MU: Chemotactic activity of the lipid peroxidation product 4-hydroxynonenal and homologous hydroxyalkenals. Biol Chem Hoppe-Seyler 1986, 367: 321-329
• Curzio M, Esterbauer H, Di Mauro C, Dianzani MU: Influence of the lipid peroxidation product 4-hydroxynonenal on human neutrophil migration. Int J Tissue React 1990, 6: 13-18
• D'Agostino RB, Kannel WB, Stephanians MN, D'Agostino LC: A comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia. Am J Cardiol 1992, 69: 28-34
• Darnell J, Lodish H, Baltimore D: Energy conversion: the formation of ATP in mitochondria and bacteria, Chapter 15, pp. 583-616, in: Darnell J, Lodish H, Baltimore D (eds): Molecular Cell biology. 1990 Second Edition
• Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J: Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993, 69: 377-381
• Decoulx E, Millaire A, de Groote P, Mahieux G, Ducloux G: Rhabdomyolyse sous pravastatine et macrocréatine kinase de type I. Ann. Cardiol. Angéiol 1993, 42(5): 267-269
• Deegan and Feely: Making sensible drug choices - horses for courses, pp.227-244 in: Betteridge DJ (ed): Lipids: Current Perspectives. Martin Duuitz Ltd., London 1996
• DePinieux G, Chariot P, Ammi-Said M, Louarn F, Lejonc JL, Astier A, Jacotot B, Gherardi R: Lipid-lowering drugs and mitochondiral function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Brit J Clin Pharmacol 1996, 42: 333-337
• DesRosiers C, Rivest MJ, Bioly M J, Jetté M, Carrobé -Cohen A, Kumar A: Gas chromatographic-mass spectrometric assay of tissue malonedialdehyde, 4-hydroxynonenal, and other aldehydes after their reduction to stable alcohols. 1993, 208(1) 161-170
• Dianzani MU: Biochemical effects of saturated and unsaturated aldehydes, pp 129-158, in: McBrian DCH, Slater TF (eds): Free radicals, lipid peroxidation and cancer. Academic Press, London, 1982
• Dianzani MU, Paradisi L, Barrera G, Rossi MA, Parola M: The action of 4-hydroxynonenal on the plasma membrane enzymes from rat hepatocytes, pp. 329-346, in: Beaumont, PC, Deeble DJ, Parsons BJ, Rice-Evans C, (eds): Free radicals, metal ions and biopolymers. Richelieu Press, London 1989
• Dianzani C, Parrini M, Ferrara C, Fantozzi R: Effect of 4-hydroxynonenal on superoxide anion production from primed human neutrophils. Cell Biochem Funct 1996, 14(3): 193-200
• Dietschy JM, Turley StD, Spady DK: Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 1993, 34: 1637-1659
• Di Mauro C, Cavalli G, Curzio M, Ferretti C, Mengozzi G, Rossi MA, Paradisi L, Dianzani MU: Evidence of 4-hydroxynonenal involvement in modulation of phagocyte activities. Int J Tissue React 1995, 17(2): 61-72
• Dix TA, Mmett LJ: Metabolism of polycyclic aromatic hydrocarbon derivatives to ultimate carcinogens during lipid peroxidation. Science 1983, 221: 77-79
• Dobretsov G, Borschebskaya T, Petrov V, Vladimirov Y: The increase of phospholipid bilayer rigidity after lipid peroxidation. FEBS Lett 1977, 84: 125-129
• Dobs AS, Sarna PS, Schteingart D: Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Metabolism 1993, 42: 1146-1152
• Dogterom P, Mulder GJ, Nagelkerke JF: Lipid peroxidation-dependent and -independent protein thiol modifications in isolated rat hepatocytes: Differential effects of vitamin E and disulfiram. Chem Biol Interact 1989, 71: 291-306
• Duggan DE, Chen I-W, Bayne WF, Halpin RA, Duncan CA, Schwartz MS, Stubbs RJ, Vickers S: The physiological disposition of lovastatin. Drug Metab Dispos 1989, 17(2): 166-173
• Eckl P, Esterbauer H: Genotoxic effects of 4-hydroxynonenals. Adv Biosci 1989; 76: 141-157
• Eddy LJ, Stewart JR, Jones HP, Engerson TD, McCord JM, Downey JM: Free radical-producing enzyme, xanthine oxidase, is undetectable in human hearts. Am J Physiol 1987, 253: H709-H711
• Edlund C, Soderberg M, Kristensson K: Isoprenoids in aging and neurodegeneration. Neurochem Int 1994, 25(1): 35-38
• Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994, 89: 2519-2524
• Egashira K, Takeshita A: Beneficial effect of cholesterol-lowering therapy on endothelium-dependent coronary vasodilation in patients with hypecholesterolemia, pp. 622-625 in: Egashira K, Takeshita (eds): Vasodilation. Ann NY Acad Sci 1994
• Eggens I, Elmberger PG, Löw P: Polyisoprenoid, cholesterol and ubiquinone levels in human hepatocellular carcinomas. Br J Exp Path 1989, 70: 83-92
• Elmberger PG, Eggens I, Dallner G: Conditions for quantitation of dolichyl phosphate, dolichol, ubiquinone and cholesterol by HPLC. Biomed Chromatogr 1989, 3(1): 20-28
• Elmberger PG, Kalén A, Appelkvist EL, Dallner G: In vitro and in vivo synthesis of dolichol and other main mevalonate products in various organs of the rat. Eur J Biochem 1987, 168: 1-11
• Elmberger PG, Kalén A, Lund E, Reihnér E, Eriksson M, Berglund L, Angelin B, Dallner G: Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia. J Lipid Res 1991, 32: 935-940
• Ely JTA, Fudenberg HH, Bliznakov EG, Branch JD: Hemorrhagic stroke in human pretreated with coenzyme Q₁₀: Exceptional recovery as seen in animal models. J Orthomol Med 1998, 13(2): 105-109
• Ericsson J, Dallner G: Distribution, biosynthesis, and function of mevalonate pathway lipids. Subcell Biochem 1993, 21: 229-272
• Ernster L, Dallner G: Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995, 1271: 195-204
• Ernster L, Forsmark-Andrée P: Ubiquinol: an endogenous antioxidant in aerobic organisms. Clin Investig 1993, 71: S60-S65
• Ernster L, Forsmark P, Nordenbrand K: The mode of action of lipid-soluble antioxidants in biological membranes: relationship between the effects of ubiquinol and vitamin E as inhibitors of lipid peroxidation in submitochondrial particles. Biofactors 1992, 3(4): 241-248
• Esposti MD, Ghelli A, Crimi M, Estornell E, Fato R, Lenaz G: Complex I and Complex III of mitochondria have common inhibitors acting as ubiquinone antagonists. Biochem Biophys Res Commun 1993, 190(3): 1090-1096
• Esterbauer H: Cytotoxicity and genotoxicity of lipid-oxidation products. Am J Clin Nutr 1993, 57 (suppl): 779S-786S
• Esterbauer H: The chemistry of oxidation of lipoproteins. pp. 55-79 in: Rice-Evans C, Bruckdorfer KR (eds) Oxidative stress. Lipoproteins and cardiovascular dysfunction, 1995
• Esterbauer H, Eckl P, Ortner A: Possible mutagenes derived from lipids and lipid precursors. Mutation Res 1990a, 238: 223-233
• Esterbauer H, Gebick IJ, Puhl H, Jüergens G: The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Rad Biol Med 1992, 13: 241-390
• Esterbauer H, Koller E, Slee RG, Koster JF: Possible involvement of the lipid-peroxidation product 4-hydroxynonenal in the formation of fluorescent chromolipids. Biochem J 1986, 239: 405-409
• Esterbauer H, Schaur RJ, Zollner H: Chemistry and biochemistry of 4-hydroxynonenal malonaldehyde and related aldehydes. Free Rad Biol Med 1991, 11: 81-128
• Esterbauer H, Zollner H, Lang J: Metabolism of the lipid peroxidation product 4-hydroxynonenal by isolated hepatocytes and by liver cytosolic fractions. Biochem J 1985, 228: 363-373
• Esterbauer H, Zollner H, Schaur RJ: Aldehydes formed by lipid peroxidation; mechanisms of formation, occurrence and determination. pp. 239-268 in: Vigo-Pelfrey C (ed): Membrane lipid oxidation, vol. 1. CRC Press, Boca Raton, Florida 1990b
• Everett DW, Chando ThJ, Didonato GC, Singhvi SM, Pan HY, Weinstein StH: Biotransformation of pravastatin sodium in humans. Drug Metab Dispos 1991, 19(4): 740-748
• Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment Panel II). JAMA 1993, 269(23): 3015-3023
• Facts and Comparisons, St. Louis, Missouri, USA Antihyperlipidemic agents: HMG-CoA reductase inhibitors. Facts and Comparisons 1997a, Feb: 171f-172a (25p)
• Ferrari R: The role of free radicals in ischaemic myocardium. British J Clin Practice 1990, 44: 301-305
• Ferrari R, Ceconi C, Curello S, Cargnoni A, Alfieri O, Pardini A, Marzollo P, Visiolo O: Oxygen free radicals and myocardial damage: Protective role of thiol-containing agents. Am J Med 1991, 91(suppl 3C): 95s-105s
• Ferro M, Marinari UM, Poli G, Dianzani MU, Fauler G, Zollner H, Esterbauer H: Metabolism of 4-hydroxynonenal by the rat hepatoma cell line MH1C1. Cell Biochem Funct 1988, 6: 245-250
• Finel M: The proton-translocating NADH: ubiquinone oxidoreductase: a discussion of selected topics. J Bioenerg Biomembr 1993, 25 (4): 357-366
• Flint OP, Masters BA, Gregg RE, Durham SK: HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol 1997, 145(1): 99-110
• Flint OP, Masters PA, Gregg RE, Durham SK: Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol 1996, 145: 91-98
• Folkers K, Langsjoen P, Willis R, Richardson Ph, Xia L-J, Ye C-Q, Tamagawa H: Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci (USA) 1990, 87 (Nov): 8931-8934
• Folkers K, Littaru GR, Ho L, Runge TM, Havanonda S, Cooley D: Evidence for a deficiency of coenzyme Q₁₀ in human heart disease. Int J Vit Nutr 1970, 40: 380-390
• Folkers K, Morita M, McRee J Jr.: The activities of coenzyme Q₁₀ and vitamin B₆ for immune responses. Biochem Biophys Res Comm 1993, 193(1): 88-92
• Folkers K, Simonsen R: Two successful double-blind trials with coenzyme Q₁₀ (vitamin Q₁₀) on muscular dystrophies and neurogenic atrophies. Biochim Biophys Acta 1995, 1271: 281-286
• Folkers K, Vadhanavikit S, Mortensen SA: Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q. Proc Natl Acad Sci (USA) 1985, 82: 901-904
• Forsmark-Andree P, Ernster L: Evidence for a protective effect of endogenous ubiquinol against oxidative damage to mitochondrial protein and DNA during lipid peroxidation. Mol Aspects Med 1994, 15(suppl): 73-81
• Frankel EN, Neff WE: Formation of malonaldehyde from lipid oxidation products. Biochim Biophys Acta 1983, 754: 264-270
• Frei B, Kim MC, Ames BN: Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. Proc Natl Acad Sci (USA) 1990, 87: 4879-4883
• Friedl HP, Smith DJ, Till GO, Thomson PD, Louis DS, Ward PA: Ischemia-reperfusion in humans. Appearance of xanthine oxidase activity. Am J Pathol 1990, 136: 491-495
• Fujioka T, Nara F, Tsujita Y, Fukushige J, Fukami M, Kuroda M: The mechanism of lack of hypocholesterolemic effects of pravastatin sodium,a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats. Biochim Biophys Acta 1995, 1254: 7-12
• Fukami M, Maeda N, Fukushige J, Kogure Y, Shimada Y, Ogawa T, Tsujita Y: Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits. Res Exp Med 1993, 193: 263 - 273
• Gabriel L, Migletta A, Dianzani MU: 4-Hydroxy-alkenals interaction with purified microtubular protein. Chem Biol Interact 1985, 56: 201-212
• Gadoni E, Olivero A, Miglietta A, Bocca C, Gabriel L: Cytoskeletal modifications induced by 4-hydroxynonenal. Cytotechnology 1993, 11(suppl 1): S62-S64
• Gerson RJ, MacDonald JS, Alberts AW, Chen J, Yudkovitz JB, Greenspan MD, Rubin LF, Bokelman DL: On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Exp Eye Res 1990, 50: 65-78
• Gerson RJ, MacDonald JS, Alberts AW, Kornbrust DJ, Majka JA, Stubbs RJ, Bokelman DL: Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors. Am J Med 1989, 87 (suppl. 4A): S28-S38
• Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, Greco AV, Littarru GP: Evidence of plasma CoQ₁₀-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993, 33: 226-229
• Ginsberg HN, Goldberg IJ: Disorders of lipoprotein metabolism. pp. 2138-2149 in: Fauci AS et al. (eds) Harrison's Principles of Internal Medicine. Vol II. McGraw-Hill, New York 1998
• Ginsberg HN, Le NA, Short MP, Ramakrishnan R, Desnick RJ: Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. J Clin Invest 1987, 80: 1692-1697
• Glasser StP, Selwyn AP, Ganz P: Atherosclerosis: risk factors and the vascular endothelium. Am Heart J 1996, 131: 379-384
• Glinn MA, Lee CP, Ernster L: Pro-and anti-oxidant activities of the mitochondrial respiratory chain: factors influencing NAD(P)H-induced lipid peroxidation. Biochim Biophys Acta 1997, 1318: 246-254
• Goldhaber JI, Weiss JN: Oxygen free radicals and cardiac reperfusion abnormalities. Hypertension 1992, 20: 118-127
• Goldstein JL, Brown MS: Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis. Circulation 1987, 76(3): 504-507
• Graaf de J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendriks JCM, Stalenhoelf AFH: Enhanced susceptibility to in vitro oxidation of the dense low-density lipoprotein subfractions in healthy subjects. Arterioscler Thromb 1991, 11: 298-306
• Grant WM: Toxicology of the eye. pp. 955-957 in: Thomas CC, Springfield 1986, 3 ed.
• Grasse LD, Lame MW, Segall HJ: In vivo covalent binding of trans-4-hydroxy-2-hexenal to rat liver macromolecules. Toxicology Letters 1985, 29: 43-49
• Gray KA, Dutton PL, Daldal F: Requirement of histidine 217 for ubiquinone reductase activity (Qi site) in the cytochrome bc₁, complex. Biochem 1994, 33: 723-733
• Grieb P, Ryba MS, Sawicki J, Chrapusta SJ: Oral coenzyme Q₁₀ administration prevents the development of ischemic brain lesions in a rabbit model of symptomatic vasospasm. Acta Neuropathol 1997, 94(4): 363-368
• Griffin DS, Segall HJ: Lipid peroxidation and cellular damage caused by the pyrrolizidine alkaloid senecionine, and the host pathology, pp 201-220, in: Rice-Evans (ed): Free radicals. Cell damage and disease. Richelieu Press; London 1986b
• Griffin DS, Segall HJ: Role of cellular calcium homeostasis in toxic liver injury induced by the pyrrolizidine alkaloid senecionine and the alkenal trans-4-OH-2-hexenal. J Biochem Toxicol 1987, 2: 155-167
• Grum CM, Gallagher KP, Kirsh MM, Shlafer M: Absence of detectable xanthine oxidase in human myocardium. J Mol Cell Cardiol 1989, 21: 263-267
• Grune T, Schönheit K, Blasig I, Siems W: Reduced 4-hydroxynonenal degradation in hearts of spontaneously hypertensive rats during normoxia and postischemic reperfusion. Cell Bioch Funct 1994, 12: 143-147
• Grune T, Siems WG, Petras T: Identification of metabolic pathways of the lipid peroxidation product 4-hydroxynonenal in in situ perfused rat kidney. J Lipid Res 1997, 38(8): 1660-1665
• Grünler J, Ericsson J, Dallner G: Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins. Biochim et Biophys Acta 1994, 1212: 259-277
• Gutteridge JM, Rowley DA, Halliwell B: Superoxide-dependent formation of hydroxyl radicals and lipid peroxidation in the presence of iron salts. Biochem J 1982, 206: 605-609
• Gutteridge JM, Wilkins S: Copper salt-dependent hydroxyl radical formation. Damage to proteins acting as antioxidants. Biochim Biophys Acta 1983, 759: 38-41
• Haberland A, Schutz AK, Schimke I. The influence of lipid peroxidation products (malondialdehyde, 4-hydroxynonenal) on xanthine oxidoreductase prepared from rat liver. Biochem Pharmacol 1992, 43(10): 2117-2120
• Haenen GRMM, Plug HJM, Vermeulen NPE, Timmerman H, Bast A: Contribution of 4-hydroxy-2,3-trans-nonenal to the reduction of b-adrenoceptor function in the heart by oxidative stress. Life Sci 1989, 45: 71-76
• Haenen GRMM, Tai Tin Tsoi JNL, Vermeulen NPE, Timmerman H, Bast A: Hydroxy-2,3-trans-nonenal stimulates microsomal lipid peroxidation by reducing the glutathione-dependent protection. Arch Biochem Biophys 1987, 259: 449-456
• Halliwell B: Antioxydants in human health and disease. Ann Rev Nutr 1996, 16: 33-50
• Halliwell B: Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 1994, 344: 721-724
• Halliwell B: How to caracterize a biologic antioxidant. Free Rad Res Comm 1990, 9: 569-571
• Halliwell B, Cross CE, Gutteridge JM: Free radicals, antioxidants, and human disease: where are we now? J Lab Clin Med 1992, 119: 589-620
• Halliwell B, Gutteridge JM: Free radicals in biology and medicine. Clarendon Press, Oxford 1989, 2 ed
• Hamsten A, Karpe F: Triglycerides and coronary heart disease - has epidemiology given us the right answer?, pp.43-68 in: Betteridge DJ (ed): Lipids: Current Perspectives. Martin Duuitz Ltd., London 1996
• Han DK, Haudenschild CC, Hong MK, Tinkle BT, Leon MB, Liau G: Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am J Pathol 1995, 147: 267-277
• Hanaki Y, Sugiyama S, Ozawa T, Ohno M: Coenzyme Q₁₀ and coronary artery disease. Clin Investig 1993, 71: S112-S115
• Hanaki Y, Sugiyama S, Ozawa T, Ohno M: Ratio of low-density lipoprotein cholesterol to ubiquinone as a coronary risk factor. NEJM 1991, 325 (11): 814-815
• Handelman GJ, Van Kuijk FJ, Chatterjee A, Krinsky NI: Characterization of products formed during autooxidation of b-carotene. Free Rad Biol Med 1991, 10: 427-437
• Haramaki N, Stewart D B, Aggarwal S, Ikeda H, Reznick A Z, Packer L: Networking antioxidants in the isolated rat heart are selectively depleted by ischemia-reperfusion. Free Rad Biol Med 1998, 25(3): 329-339
• Haria M and McTavish D: Pravastatin: A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs 1997, 53(2): 299-336
• Harris ED: Regulation of antioxydant enzymes. FASEBJ 1992, 6: 2675-2683
• Hartley DP, Petersen DR: Metabolic interactions of 4-hydroxynonenal, acetaldehyde and glutathione in isolated liver mitochondria. Adv Exp Med Biol 1993, 328: 27-36
• Hatefi Y: The mitochondrial electron transport and oxidative phosphorylation system. Ann Rev Biochem 1985, 54: 1015-1069
• Hauptlorenz S, Esterbauer H, Moll W, Pümpel R, Schauenstein E, Puschendorf B: Effects of the lipid peroxidation product 4-hydroxynonenal and related aldehydes on proliferation and viability of cultured Ehrlich ascites tumor cells. Biochem Pharmacol 1985, 34: 3803-3809
• Havel RJ, Kane JP: Introduction: Structure and metabolism of plasma lipoproteins. pp. 1841-1851 in: Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The metabolic and molecular basis of inheritated disease. McGraw-Hill, NY 1995
• He DY, Yu L, Yu Ch-A: Ubiquinone binding domains in bovine heart mitochondrial cytochrome b. J Biol Chem 1994, 269(3): 2292-2998
• He Q, Khanna P, Srivastava S, van Kuijk FJ, Ansari NH: Reduction of 4-hydroxynonenal and 4-hydroxyhexenal by retinal aldose reductase. Biochem Biophys Res Commun 1998, 247(3): 719-722
• Heart and Stroke Foundation of Canada. Heart disease and stroke in Canada, Heart and Stroke Foundation of Canada, Ottawa, ON: 1995.
• Henderson A: Coronary heart disease: Overview. Lancet, 1996, 348 (November): S1-S31
• Henry P: Hypercholesterolemia and Angiogenesis. Am J Cardiol 1993, 72: 61C-64C
• Himber J, Missano B, Rudling M, Hennes U, Kempen HJ: Effects of stigmastanyl-phosphocholine (Ro 16-6532) and lovastatin on lipid and lipoprotein levels and lipoprotein metabolism in the hamster on different diets. J Lipid Res 1995, 36: 1567-1585
• Hoeg JM et al.: Neomycin and plasma lipoproteins in type II hyperlipoproteinemia. Clin Pharmacol Ther 1984, 36: 555-559
• Hoff HF, O'Neil J: Structural and functional changes in LDL after modification with both 4-hydroxynonenal and malondialdehyde. J Lipid Res 1993, 34(7): 1209-1217
• Hoff HF, Cole TB: Macrophage uptake of low-density lipoprotein modified by 4-hydroxynonenal. An ultrastructural study. Lab Invest 1991, 64(2): 254-264
• Hoff HF, O'Neill J, Chisolm GM III, Cole TB, Quehenberger O, Esterbauer H, Jürgens G: Modification of LDL with 4-hydroxynonenal induces uptake by macrophages. Arteriosclerosis 1989, 9: 538-549
• Hoffman R, Brook GJ, Aviram M: Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and in vivo studies. Atherosclerosis 1992, 93: 105-113
• Horwitz LD, Fennessey PV, Shikes RH, Kong Y: Marked reduction in myocardial infarct size due to prolonged infusion of an antioxidant during reperfusion. Circ 1994, 89(4): 1792-1801
• Humphries KM, Yoo Y, Szweda LI: Inhibition of NADH-linked mitochondrial respiration by 4-hydroxy-2-nonenal. Biochemistry 1998, 37(2): 552-557
• Hunninghake DB, Lovastatin Study Group II: Therapeutic response to lovastatin in nonfamilial hypercholesterolemia: a multicenter study. JAMA 1986, 256: 2829-2834
• Hunninghake DB, Mellies MJ, Golberg AC, Kuo PT, Kostis JB, Schrott HG, Insull W, Pan HY: Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing. Arteriosclerosis 1990, 85: 257-262
• Hurst JS, Slater TF, Lang J, Jürgens G, Zollner H, Esterbauer H: Effects of the lipid peroxidation product 4-hydroxynonenal on the aggregation of human platelets. Chem Biol Interact 1987, 61: 109-124
• Hussein O, Brook JG, Aviram M: Intraperitoneal injection of platelet secretory products into mice increases macrophage uptake or oxidized low density lipoprotein. Isr J Med Sel 1993, 29: 453-459
• Hussein O, Rosenblat M, Schlezinger S, Keidar S, Aviram M: Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br Clin Pharmacol 1997a, 44: 77-83
• Hussein O, Schlezinger S, Rosenblat M, Keidar S, Aviram M: Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 1997b, 128: 11-18
• Ikenoya S, Takada M, Yuzuriha T, Abe K, Katayama K: Studies on reduced and oxidized ubiquinones. I. Simultaneous determination of reduced and oxidized ubiquinones in tissues and mitochondria by HPLC. Chem Pharm Bull 1981, 29(1): 158-164
• Iliou JP, Thollon C, Villeneuve N, Robin F, Cambarrat C, Jacquemin C, Vilaine JP: Monohydroperoxidized fatty acids but not 4-hydroxynonenal induced acute cardiac cell damage. Free Rad Biol Med 1995, 19(6): 773-783
• Ingold KU, Bowry VW, Stocker R, Walling C: Autoxidation of lipids and antioxidation by alpha-tocopherol and ubiquinol in homogeneous solution and in aqueous dispersions of lipids: unrecognized consequences of lipid particle size as exemplified by oxidation of human low density lipoprotein. Proc Natl Acad Sci (USA) 1993, 90(1): 45-49
• Ishikawa T, Esterbauer H, Sies H: Role of cardiac glutathione transferase and of the glutathione S-conjugate export system in biotransformation of 4-hydroxynonenal in the heart. J Biol Chem 1986, 261: 1576-1586
• Jacoby W, Habig W: Glutathion S transferases. pp. 63-94 in: Jacoby W (ed): Enzymatic basis of detoxication, vol. II, Academic Press, New York 1980.
• Jones PJH, Schoeller DA: Evidence for diurnal periodicity in human cholesterol synthesis. J Lipid Res 1990, 31: 667-673
• Jong de JW, van der Meer P, Nieukoop AS, Huizer T, Stoeve RJ, Bos E: Xanthine oxidoreductase activity in perfused hearts of various species, including humans. Circ Res 1990, 67: 770-773
• Jorge PA, Osaki MR, de Almeida E, Credidio-Neto L, Metze K: Effects of vitamin E on endothelium-dependent coronary flow in hypercholesterolemic dogs. Atherosclerosis 1996, 126(1): 43-51
• Jorge PAR, Osaki MR, Metze K: Effects of simvastatin and pravastatin on endothelium-dependent relaxation in hypercholesterolemic rabbits. Exp Toxicol Pathol 1994, 46: 465-469
• Judy WV, Hall JH, Toth PD, Folkers K: Long term management of end stage heart failure with coenzyme Q₁₀. pp. 291-302 in: Folkers K, Yamamura Y (eds): Biomedical and Clinical Aspects of Coenzyme Q, Volume 5. Elsevier Science Publishers 1986
• Judy WV, Stogsdill WW, Folkers K: Myocardial preservation by therapy with coenzyme Q₁₀ during heart surgery. Clin Investig 1993, 71: S155-S161
• Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, Jansen H, Boerma GJM, van Rappard FM, Lie KI: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. (REGRESS) Circulation 1995, 91: 2528-2540
• Jurgens G, Chen Q, Esterbauer H, Mair S, Ledinski G, Dinges HP: Atherogenic lipoproteins in man: Immunostaining of human autopsy aorta with antibodies to modified apolipoprotein B and apolipoprotein (a). Arterioscler Thromb 1993, 13: 1689-1699
• Kagan VE, Arroyo A, Tyurin VA, Tyurina YY, Villalba JM, Navas P: Plasma membrane NADH-coenzyme Q_o reductase generates semiquinone radicals and recycles vitamin E homologue in a superoxide-dependent reaction. FEBS Lett 1998, 428(1-2): 43-46
• Kagan V, Serbinova E, Packer L: Antioxidant effects of ubiquinones in microsomes and mitochondria are mediated by tocopherol recycling. Biochem Biophys Res Commun 1990, 169(3): 851-857
• Kagan VE, Serbinova EA, Stoyanovsky DA, Khwaja S, Packer L: Assay of ubiquinones and ubiquinols as antioxidants. Meth Enzymol 1994, 234: 343-54
• Kai MH, Eto TA, Kondo KH, Setoguchi Y, Higashi S, Maeda Y, Setoguchi T: Synchronous circadian rythms of mRNA levels and activities of cholesterol 7a-hydroxylase in the rabbit and rat. J Lipid Res 1995, 36: 367-374
• Kaikkonen J, Kosonen L, Nyyssonen K, Porkkala-Sarataho E, Salonen R, Korpela H, Salonen JT: Effect of combined coenzyme Q₁₀ and d-alpha-tocopheryl acetate supplementation on exercise-induced lipid peroxidation and muscular damage: A placebo-controlled double-blind study in marathon runners. Free Rad Res 1998, 29(1): 85-92
• Kakkis JL, Ke B, Dawson S, Maggard M, Si M, Kaldas F, Cai W, Shau H, Seu P, Sauri H, Busuttil RW, Imagawa DK: Pravastatin increase survival and inhibits natural killer cell enhancement factor in liver transplanted rats. J Surg Res 1997, 69: 393-398
• Kalén A, Appelkvist E-L, Dallner G: The effects of inducers of the endoplasmic reticulum, peroxisomes and mitochondria on the amounts and synthesis of ubiquinone in the rat liver subcellular membranes. Chem Biol Interact 1990, 73: 221-234
• Kanazawa T, Koh M, Kato M, Mikuniya A, Onodera K: A study on myocardial energy metabolism in ischemic heart disease - the effects of large dose administration of CoQ₁₀, pp. 273-280 in: K. Folkers and Y. Yamanura (eds): Biomedical and Clinical Aspects of Coenzyme Q, Vol. 4., Elsevier Science Publishers B.V.1984
• Kaneko T, Honda S, Nakano S, Matsuo M: Lethal effects of a linoleic acid hydroperoxide and its autoxidation products, unsaturated aliphatic aldehydes, on human diploid fibroblasts. Chem Biol Interact 1987, 63(2): 127-137
• Kaneko T, Kaji K, Matsuo M: Cytotoxicities of a linoleic acid hydroperoxide and its related aliphatic aldehydes toward cultured human umbilical vein endothelial cells. Chem Biol Interact 1988, 67: 295-304
• Kanner J, German JB, Kinsella JF: Indication of lipid peroxidation in biological systems. CRC Crit Rev Food Sci Nutr 1987, 25: 317-346
• Karlhuber GM, Bauer HC, Eckl PM: Cytotoxic and genotoxic effects of 4-hydroxynonenal in cerebral endothelial cells. Mutat Res 1997, 381(2): 209-216
• Karlsson J, Diamant B, Folkers K, Edlund PO, Lund B, Theorell H: Skeletal muscle and blood CoQ₁₀ in health and disease. pp. 288-295 in: Lenaz G, Barnabei O, Battino M (eds): Taylor and Francis, London 1990.
• Karlsson J, Liska J, Gunnes S, Koul B, Semb B, Aström H, Diamant B, Folkers K: Heart muscle ubiquinone and plasma antioxidants following cardiac transplantation. Clin Investig 1993, 71: S76-S83
• Karlsson J, Semb B: Heart muscle and plasma vitamin Q with heart transplantation. Can J Cardiol 1997, 13(2): 147-152
• Kehrer JP: Free radicals as mediators of tissue injury and disease. Crit Rev Toxicol 1993, 23(1): 21-48
• Keller JN, Mattson MP: Roles of lipid peroxidation in modulation of cellular signaling pathways, cell dysfunction, and death in the nervous system. Rev Neurosci 1998, 9(2): 105-116
• Keller JN, Pang Z, Geddes JW, Begley JG, Germeyer A, Waeg G, Mattson MP: Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta peptide: role of the lipid peroxidation product 4-hydroxynonenal. J Neurochem 1997, 69(1): 273-284
• Khoschsorur G, Schaur R, Schauenstein E, Tillian HM, Reiter M: Intracellular effects of hydroxyalkenals on animal tumors. Z Naturforsch 1981, 36: 572-578
• Kikugawa K, Beppu M: Involvement of lipid oxidation products in the formation of fluorescent and cross-linked protein. Chem Phys Lipids 1987, 44: 277-296
• Kirby TJ: Cataracts produced by triparanol. Trans Am Ophthalmol Soc 1967, 65: 493-543
• Kishi T, Takahashi T, Okamoto T: Cytosolic NADPH-UQ reductase-linked recycling of cellular ubiquinol: its protective effect against carbon tetrachloride hepatoxicity in rat. Molec Aspects Med 1997, 18(suppl): S71-S77
• Kita T, Brown MS, Bilheimer DW, Goldstein JL: Delayed clearance of very low density and intermediate density lipoproteins with enhanced conversion to low density lipoprotein in WHHL rabbits. Proc Natl Acad Sci 1982, 79: 5693-5697
• Kleinveld HA, Demacker PNM, Stalenhoef AFH: Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb 1994, 14: 1386-1391
• Kobashigawa AJ, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasak PI, Sabad A, Cogert GA, Trosian K, Hamilton MA, Moriguchi JD, Kawata N, Hagwe A, Drinkwater DC, Stevenson LW: Effect of pravastatin on outcomes after cardiac transplantation. NEJM 1995, 333(10): 621-627
• Koga T, Fukuda K, Shimada Y, Fukami M, Koike H, Tsujita Y: Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. Eur J Biochem 1992, 209: 315-319
• Koga T, Kikuchi T, Miyazaki A, Koike H: Tissue-selective inhibition of sterol synthesis in mice by pravastatin sodium after a single or repeated oral administrations. Lipids 1995, 30(8): 775-779
• Koga T, Shimada Y, Kuroda M, Tsujita Y, Hasegawa K, Yamazaki M: Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium,a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta 1990, 1045: 115-120
• Komai T, Kawai K, Tokui T, Tokui Y, Kuroiwa C, Shigehara E, Tanaka M: Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys. Eur J Drug Metab Pharmaco 1992, 17(2): 103-112
• Komai T, Tsujita Y: Hepatocyte selectivity of HMG-CoA reductase inhibitors. D N & P 1994, 7(5): 279-288
• Kontush A, Hübner C, Finckh B, Kohlschütter A, Beisiegel U: How different constituents of low density lipoprotein determine its oxidizability by copper: a correlational approach. Free Rad Res 1996, 24 (2): 135-147
• Kontush A, Reich A, Baum K, Spranger T, Finckh B, Kohlschütter A, Beisiegel U: Plasma ubiquinol-10 is decreased in patients with hyperlipidaemia. Atherosclerosis 1997, 129: 119-126
• Kornburst DJ, MacDonald JS, Peter CP, Duchai DM, Stubbs RJ, Germershausen JI, Alberts AW: Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. J Pharmacol Exp Ther 1989, 248(2): 498-505
• Korthuis RJ, Granger DN: Reactive oxygen metabolites, neutrophils, and the pathogenesis of ischemic-tissue/reperfusion. Clin Cardiol 1993, 16: I19-I26
• Koster JF, Slee RG, Montfoort A, Lang J, Esterbauer H: Comparison of the inactivation of microsomal glucose-6-phosphatase by in situ lipid peroxidation-derived 4-hydroxynonenal and exogenous 4-hydroxynonenal. Free Rad Res Comms 1986, 1: 273-287
• Kowaltowski AJ, Castilho RF, Vercesi AE: Ca²⁺-induced mitochondrial membrane permeabilization: role of coenzyme Q redox state. Am J Physiol 1995, 269(Cell Physiol 38): C141-C147
• Kraaij van der AMM, de Jonge HR, Esterbauer H, de Vente J, Steinbusch HWM, Koster JF: Cumene hydroperoxide, an agent inducing lipid peroxidation, and 4-hydroxy-2,3-nonenal, a peroxidation product, cause coronary vasodilation in perfused rat hearts by a cyclic nucleotide-independent mechanism. Cardiovasc Res 1990, 24: 144-150
• Krause BR, Princen HMG: Lack of predictability of classical animal models for hypolipidemic activity: A good time for mice? Atherosclerosis 1998, 140(1): 15-24
• Krinsky NI: Mechanism of action of biological antioxidants. Proc Soc Exp Biol Med 1992, 200: 248-254
• Krinsky NI: Membrane antioxidants. Ann NY Acad Sci 1988, 551: 17-33
• Krokan H, Grafström RC, Sundqvist K; Esterbauer H, Harris CC: Cytotoxicity, thiol depletion and inhibition of o-6-methylguanine-DNA methyltransferase by various aldehydes in cultured human bronchial fibroblasts. Carcinogenesis 1985, 6: 755-759
• Kugiyama K, Kerns SA, Morriset JD, Roberts R, Henry PD: Impairment of endothelium-dependent relaxation by lysolecithin in modified LDL. Nature 1990, 334: 160-162
• Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijf P, McPherson R, Bruschke AVG, Lie KI, Kastelein JJP: The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. NEJM 1998, 338(2): 86-93
• Kukreja RC, Hess ML: The oxygen free radical system: From equations through membrane-protein interactions to cardiovascular injury and protection. Cardiovasc Res 1992, 26: 641-655
• Laaksonen R, Fogelholm M, Himberg JJ, Laakso J, Salorinne Y: Ubiquinone supplementation and exercise capacity in trained young and older men. Eur J Appl Physiol Occup Physiol 1995, 72(1-2): 95-100
• Lagendijk J, Ubbink JB, Delport R, Hayward Vermaak WJ, Human JA: Ubiquinol/ubiquinone ratio as marker of oxidative stress in coronary artery disease. Research Communications in Molecular Pathology and Pharmacology 1997, 95(1) 11-20
• Lagendijk J, Ubbink JB, Hayward Vermaak WJ: Measurement of the ratio between the reduced and oxidized forms of coenzyme Q₁₀ in human plasma as a possible marker of oxidative stress. J Lipid Res 1996, 37: 67-75
• Lame MW, Segall HJ: In vitro effects of trans-4-hydroxy-2-alkenals on mouse liver cytochrome P-450. Chem Biol Interact 1987, 62: 59-74
• Landi L, Fiorentini D, Galli MC, Segura-Aguilar J, Beyer RE: DT-Diaphorase maintains the reduced state of ubiquinones in lipid vesicles, thereby, promoting their antioxidant function. Free Rad Biol Med 1997, 22(1-2): 329-335
• Lang JK, Gohil K, Packer L: Simultaneous determination of tocopherols, ubiquinols and ubiquinones in blood, plasma, tissue homogenates, and subcellular fractions. Analytical Biochemistry 1986, 157: 106-116
• Lang JK, Packer L: Quantitative determination of vitamin E and oxidized and reduced coenzyme Q by high-performance liquid chromotography with in-line ultraviolet and electrochemical detection. J Chromatogr 1987, 385: 109-117
• Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T,Langsjoen P: Effective and safe therapy with coenzyme Q₁₀ for cardiomyopathy. Klin Wochenschr 1988, 66: 583-590
• Langsjoen PH, Langsjoen PH, Folkers K: Isolated diastolic dysfunction of the myocardium and its response to CoQ₁₀ treatment. Clin Investig 1993, 71: 140-144
• Langsjoen PH, Langsjoen PH, Folkers K: Long-term efficacy and safety of coenzyme Q₁₀ therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1990, 65: 521-523
• Langsjoen H, Langsjoen P, Langsjoen P, Willis R, Folkers K: Usefulness of coenzyme Q₁₀ in clinical cardiology: a long-term study. Molec Aspects Med 1994, 15(suppl): 165S-175S
• Lass A, Sohal RS: Electron transport-linked ubiquinone-dependent recycling of alpha-tocopherol inhibits autooxidation of mitochondrial membranes. Arch Biochem Biophys 1998, 352(2): 229-236
• Laufs U, La-Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 1998, 97(12): 1129-1135
• Laughlin RC, Carey TF: Cataracts in patients treated with triparanol. JAMA 1962, 181(4): 339-340
• Léger CL: Vitamine E, tocophérols et composés apparentés. Propriétés antioxygène et rôle biologique. Sources alimentaires. CNRS-CNERNA, Commission Nutrition Membranes. Polytechnica, Paris 1992
• Lenaz G, Espoti MD: Physical properties of ubiquinone in model system and membranes. pp. 83-106 in: Lenaz G (ed): Coenzyme Q: biochemistry, bioenergetics and clinical applications of ubiquinone. John Wiley & Sons, New York 1985
• Lenaz G, Fato R, Castelluccio C, Cavazzoni M, Estornell E, Huertas JF, Pallotti F, Parenti Castelli G, Rauchova H: An updating of the biochemical function of coenzyme Q in mitochondria. Molec Aspects Med 1994, 15 (suppl): S29-S36
• Lenaz G, Fato R, Castelluccio C, Genova ML, Bovina C, Estornell E, Valls V, Pallotti F, Parenti Castelli G: The function of coenzyme Q in mitochondria. Clin Investig 1993, 71: S66-S70
• Lennernäs H, Fager G: Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and Differences. Clin Pharmacokinet 1997, 32 (5): 403-425
• Leray C, Andriamampandry MD, Freund M, Gachet C, Cazenave JP: Simultaneous determination of homologues of vitamin E and coenzyme Q and products of alpha-tocopherol oxidation. J Lipid Res 1998, 39(10): 2099-2105
• Leurs R, Rademaker B, Kramer K, Timmerman H, Bast A: The effects of 4-hydroxy-2,3-trans-nonenal on b-adrenoreceptors of rat lung membranes. Chem Biol Interact 1986, 59: 211-218
• Levine GN, Keaney JF Jr, Vita JA: Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. NEJM 1995, 332(8): 512-521
• Litt MR, Jeremy RW, Weisman HF, Winkelstein JA, Becker LC: Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Evidence for neutrophil-mediated reperfusion injury. Circulation 1989, 80: 1816-1827
• Littarru GP, Battino M, Tomasetti M, Mordente A, Santini S, Oradei A, Manto A, Ghirlanda G: Metabolic implications of coenzyme Q₁₀ in red blood cells and plasma lipoproteins. Molec Aspects Med. 1994, 15(suppl) S67-S72
• Lönnrot K, Holm P, Lagerstedt A, Huhtala H, Alho H: The effects of lifelong ubiquinone Q₁₀ supplementation on the Q₉ and Q₁₀ tissue concentrations and life span of male rats and mice. Biochem Mol Biol Int 1998a, 44(4): 727-737
• Lönnrot K, Porsti I, Alho H, Wu X, Hervonen A, Tolvanen JP: Control of arterial tone after long-term coenzyme Q₁₀ supplementation in senescent rats. J Pharmacol 1998b, 124(7): 1500-1506
• Loop RA, Anthony M, Willis RA, Folkers K: Effects of ethanol, lovastatin and coenzyme Q₁₀ treatment on antioxidants and TBA reactive material in liver of rats. Molec Aspects Med 1994, 15(suppl): S195-S206
• Löw P, Andersson M, Edlund C, Dallner G: Effects of mevinolin treatment on tissue dolichol and ubiquinone levels in the rat. Biochim Biophys Acta 1992, 1165: 102-109
• Lucas DT, Szweda LI: Cardiac reperfusion injury: Aging, lipid peroxidation, and mitochondrial dysfunction. Proc Natl Acad Sci (USA), 1998, 95(2): 510-514
• Lucchesi BR: Modulation of leukocyte-mediated myocardial reperfusion injury. Ann Rev Physiol 1990, 52: 561-576
• Lyons TJ: Glycation and oxidation: a role in the pathogenesis of atherosclerosis. A symposium: Antioxidants and Lipid Metabolism. Gotto AM (ed):Am J Cardiol 1993, 71: 26B-31B
• Ma PTS, Gil G, Südhof TC, Bilheimer DW, Goldstein JL, Brown MS: Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci 1986, 83: 8370-8374
• MacDonald JS, Gerson RJ, Kornbrust DJ, Kloss MW, Prahalada S, Berry PH, Alberts AW, Bokelman DL: Preclinical evaluation of lovastatin. Am J Cardiol 1988, 62: 16J-27J
• Maggard MA, Ke B, Wang T, Kaldas F, Seu P, Busuttil RW, Imagawa DK: Effects of pravastatin on chronic rejection of rat cardiac allografts. Transplantation 1998, 65(2): 149-155
• Maltese WA: Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J 1990, 4(15): 3319-3328
• Manninen V, Olli Elo M, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988, 260(5): 641-651
• Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, Frick MH: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992, 85: 37-45
• Marinari UM, Melloni E, Patrone M, Pronzato MA, Domenicotti C, Cottalasso D, Poli G: Impairment of rat hepatocyte protein kinase c activity by CC14 and lipid peroxidation-derived aldehydes. International Symposium on Free Radicals in Medicine, Vienna 1988
• Marinari UM, Pronzato MA, Dapino D, Gazzo P, Traverso N, Cottalasso D, Odetti P: Effects of simvastatin on liver and plasma levels of cholesterol, dolichol and ubiquinol in hypercholesterolemic rats. Ital J Biochem. 1995, 44(1): 1-9
• Mark RJ, Lovell MA, Markesbery WR, Uchida K, Mattson MP: A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid b-peptide. J Neurochem 1997, 68: 255-264
• Marnett LJ, Hurd HK, Hollstein MC, Levin DE, Esterbauer H, Ames BH: Naturally occurring carbonyl compounds are mutagens in the Salmonella tester strain TA 104. Mutation Res 1985, 148: 25-34
• Martensson J, Jain A, Meister A: Glutathione is required for intestinal function. Proc Natl Acad Sci (USA) 1990, 87: 1715-1719
• Massy ZA, Keane WF, Kasiske BL: Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet 1996, 347: 102-103
• Masters BA, Palmoski MJ, Flint OP, Gregg RE, Wang-Iverson D, Durham SK: In vitro myotoxicity of the 3-hydroxy-3-methlyglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 1995, 131: 163-174
• Mayumi T, Schiller HJ, Miyachi M, Bulkley GB: Clinical application of free radical ablation for the prevention of reperfusion injury. pp. 173-187 in: Yagi K (ed): Active Oxygens, Lipid Peroxides and Antioxidants. CRC Press, Boca Raton 1993
• McCord JM: Oxygen-derived free radicals in postischemic tissue injury. NEJM 1985, 312: 159-163
• McCord JM, Turrens JF: Mitochondrial injury by ischemia and reperfusion. Curr Topics Bioenergetics 1994, 17: 173-195
• McDowell IF, Brennan GM, McEneny J, Young IS, Nicholls DP, McVeigh GE, Bruce I, Trimble ER, Johnston GD: The effect of probucol and vitamin E treatment on the oxidation of low-density lipoprotein and forearm vascular responses in humans. Eur J Clin Invest 1994, 24(11): 759-765
• Meyers DG, Maloley PA: The antioxidant vitamins: impact on atherosclerosis. Pharmacotherapy 1993, 13(6): 574-582
• Mohazzab-H KM, Kaminski PM, Fayngersh RP, Wolin MS: Oxygen-elicited responses in calf coronary arteries: Role of H₂O₂ production via NADH-derived superoxide. Am J Physiol 1996, 270: H1044-H1053
• Mohazzab-H KM, Kaminski PM, Wolin MS: Lactate and PO₂ modulate superoxide anion production in bovine cardiac myocytes. Potential role of NADH-oxidase. Circulation 1997, 96: 614-620
• Mohazzab-H KM, Kaminski PM, Wolin MS: NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J. Physiol 1994, 266: H2568-H2572
• Mohr D, Bowry VW, Stocker R: Dietary supplementation with coenzyme Q₁₀ results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim Biophys Acta 1992, 1126(3): 247-254
• Moncelli MR, Herrero R, Becucci L, Guidelli R: Kinetics of electron and proton transfer to ubiquinone-10 and from ubiquinol-10 in a self-assembled phosphatidylcholine monolayer. Biochim Biophys Acta Bioenerg 1998, 1364(3): 373-384
• Moore K, Roberts LJ II: Measurement of lipid peroxidation. Free Rad Res 1998, 28(6): 659-671
• Morand OH, Aebi JD, Dehmlow H, Ji Y-H, Gains N, Lengsfeld H, Himber J: Ro 48-8071, a new 2,3-oxidosqualene: lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin. J. Lipid Res 1997, 38: 373-390
• Morrison RA, Singhvi SM: Pharmacokinetics and oral bioavailability of pravastatin in dogs. Int J Pharm 1996, 143(2): 265-269
• Mortensen SA: Perspectives on therapy of cardiovascular diseases with coenzyme Q₁₀ (ubiquinone). Clin Investig 1993, 71: S116-S123
• Mortensen SA, Bouchelouche P, Muratsu K, Folkers K: Clinical decline and relapse of cardiac patients on coenzyme Q₁₀ withdrawal. pp. 281-290 in: Folkers K, Yamamura Y (eds): Biomedical and Clinical Aspects of Coenzyme Q, Volume 5 Elsevier Science Publishers 1986
• Mortensen SA, Leth A, Agner E, Rohde M: Dose related decrease of serum coenzyme Q₁₀ during treatment with HMG-CoA reductase inhibitors. Molec Aspects Med 1997, 18(suppl): S137-S144
• Mortensen SA, Vadhanavikit S, Muratsu K, Folkers K: Coenzyme Q₁₀: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. Int J Tiss React 1990, XII(3): 155-162
• Mosley ST, Kalinowski SS, Schafer BL, Tanaka RD: Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens. J Lipid Res 1989, 30: 1411-1420
• Muratsu K, Komorowski J, Zong-xuan S, Folkers K: A superior analysis of coenzyme Q₁₀ in blood of humans, rabbits and rats for research. BioFactors 1988, 1(2) 157-159
• Murray CE, Jennings RB, Reimer KA: Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986, 74: 1124-1136
• Muscari C, Magnani B, Biagetti L, Stefanelli C, Capucci A, Caldarera CM: Protective effect of coenzyme Q administration and relationship with its reduced biosynthesis in the ischemic and reperfused myocardium. pp. 301-310 in: Folkers K, Littaru GP, Yamagami T (eds): Biomedical and Clinical Aspects of Coenzyme Q. Elsevier Science Publishers 1991
• Nagata Y, Hidaka Y, Ishida F, Kamei T: Effects of simvastatin (MK-733) on branched pathway of mevalonate. Japan J Pharmacol 1990, 54: 315-324
• Nakahara K, Kuriyama M, Sonodo Y, Yoshidome H, Nakagawa H, Fujiyawa J, Higuchi I, Osame M: Myopathy induced by HMG-CoA reductase inhibitors in rabbits: A pathological, electrophysiological and biochemical study. Toxicol Appl Pharmacol 1998, 152(1): 99-106
• Nakahara K, Kuriyama M, Yoshidome H, Nagata K, Nagado T, Nakagawa M, Arimura K, Higuchi I, Osame M: Experimental simvastatin-induced myopathy in rabbits. J Neurol Sci 1992, 113: 114-117
• Nakahara K, Yada T, Kuriyama M, Osame M: Cytosolic Ca²⁺ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors. Biochem Biophys Res Commun 1994, 202: 1579-1585
• Napoli C: Low density lipoprotein oxidation and atherogenesis: From experimental models to clinical studies. G Ital Cardiol 1997, 27(12): 1302-1314
• Napoli C, Leccese M, Palumbo G, de Nigris F, Chiariello P, Zuliani P, Somma P, Di Loreto M, De Matteis C, Cacciatore F, Abete P, Liguori A, Chiariello M, D'Armiento FP: Effects of vitamin E and HMG-CoA reductase inhibition on cholesteryl ester transfer protein and lecithin-cholesterol acyltransferase in hypercholesterolemia. Coronary Art Dis 1998, 9(5): 257-264
• Neuvonen PJ, Kantola T, Kivisto KT: Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998, 63(3): 332-341
• Niibori K, Yokoyama H, Crestanello JA, Whitman GJR: Acute administration of liposomal coenzyme Q₁₀ increases myocardial tissue levels and improves tolerance to ischemia reperfusion injury. J Surg Res 1998, 79(2): 141-145
• Niki E, Noguchi N: Dynamics of oxidation of LDL and its inhibition by antioxidants. BioFactors 1997, 6: 201-208
• Nohl H: A novel superoxide radical generator in heart mitochondria. FEBS letters 1987, 214: 269-273
• Nohl H, Gille L. Evaluation of the antioxidant capacity of ubiquinol and dihydrolipoic acid. Z Naturforsch (C) 1998, 53(3-4): 250-253
• Nohl H, Gille L, Kozlov AV: Antioxidant-derived prooxidant formation from ubiquinol. Free Rad Biol Med 1998, 25(6): 666-675
• Nohl H, Gille L, Staniek K: Endogenous and exogenous regulation of redox-properties of coenzyme Q. Molec Aspects Med 1997, 18(suppl): S33-S40
• Noshiro M, Nishimoto M, Okuda K: Rat liver Cholesterol 7a-hydroxylase. Pretranslational regulation for circadian rhythm. J Biol Chem 1990, 265(17): 10036-10041
• Nozaki S, Vega GL, Haddox RJ, Dolan ET, Grundy SM: Influence of lovastatin on concentrations and composition of lipoprotein subfractions. Atherosclerosis 1990, 84: 101
• Oarada M, Miyazawa T, Fujimoto K, Ito E, Terao K, Kaneda T: Degeneration of lymphoid tissues in mice with the oral intake of low molecular weight compounds formed during oil autooxidation. Agr Biol Chem 1988, 52: 2101-2102
• Ogura Y, Takagi K, Kawarada Y, Mizumoto R: Pathophysiological effect of hepatic ischemia and reperfusion after hepatectomy in dogs with obstructive jaundice, focusing on the effect of coenzyme Q₁₀ and styrene-co-maleic acid superoxide dismutase. J Gastroenterol 1996, 31: 379-386
• Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, O'Grady P, Krekler M, Mangold B, Christians U: Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997, 62: 311-321
• Oliver MF, MAAS investigators: Effects of Simvastatin on coronary atheroma: the Multicenter Anti-Atheroma Study (MAAS). Lancet 1994, 344: 633-638
• Olsson JM, Eriksson LC, Dallner G: Lipid compositions of intracellular membranes isolated from rat liver nodules in Wistar rats. Cancer Res 1991, 51(14): 3774-3780
• Oms P, Assie N, Brumequel F, Degryse AD, van Haverbeke G, Delhon A: Biochemical changes and morphological alterations of liver and kidney in hamsters after administration of the HMG-CoA reductase inhibitor, simvastatin: Prevention and reversibility by mevalonate. Pharmacology & Toxicology 1995, 77: 391-396
• Orrenius S, Mc Conkey D, Bellomo G, Nicotera P: Role of Ca⁺⁺ in toxic cell killing. Trends Pharmacol Sci 1989, 10: 281-285
• Oshiro S, Nakaijima H: Intra-hepatocellular site of the catabolism of heme and globulin moiety of hemoglobin-heptoglobin after intravenous administration to rats. J Biol Chem 1988, 263: 16032-16038
• Otto J, Ordovas JM, Smith D, van Dongen D, Nicolosi RJ, Schaefer EJ: Lovastatin inhibits diet induced atherosclerosis in F1B golden Syrian hamsters. Atherosclerosis 1995, 114(1): 19-28
• Owen K, Pick CR, Libretto SE, Adams MJ: Toxicity of a novel HMG-CoA reductase inhibitor in the common marmoset (Callithrix jacchus). Hum Exp Toxicol, 1994, 13(5): 357-368
• Packard CJ: Plasma lipid and lipoprotein metabolism in the 1990s - what we know and what we need to know. pp. 1-20 in: Betteridge DJ (ed): Lipids: Current Perspectives. Martin Duuitz Ltd., London 1996
• Packer JE, Mahood JS, Mora-Arellano CO et al: Free radicals and singlet-oxygen scavengers: reaction of a peroxy-radical with b-carotene, diphenylfuran and 1,4-diazobicyclo (2,2,2)-octane. Biochem Biophys Res Commun 1989, 98: 901-906
• Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, Witzum JL: ApoE-deficient mice are a model of lipoprotein oxidation in atherosclerosis. Arterioscler Thromb 1994, 14: 605-616
• Palinski W, Rosenfeld ME, Ylä-Herrttuala S, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D: Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci 1989, 86: 1372-1376
• Palomäki A, Malminiemi K, Metsä-Ketelä T: Enhanced oxidizability of ubiquinol and a-tocopherol during lovastatin treatment. FEBS Lett 1997, 410(2-3): 254-258
• Palomäki A, Malminiemi K, Solakivi T, Malminiemi O: Ubiquinone supplementation during lovastatin treatement: Effect on LDL oxidation ex vivo. J Lipid Res 1998, 39(7): 1430-1437
• Patsch JR, Gotto Jr AM: Metabolism of high density lipoproteins. New Compr Biochem 1987, 14: 221-259
• Pedersen TR, Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344: 1383-1389
• Pedreño J, Sánchez JL, Zambón D, Ros E: In-vitro effect of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors on non-hepatic LDL receptor activity: evidence of lack of stimulatory effect of pravastatin. Coronary Artery Disease 1994, 5(12): 971-977
• Pentikainen PJ, Saraheimo M, Schwartz JI, Amin RD, Schwartz MS, Brunner-Ferber F, Rogers JD: Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol 1992, 32: 136-140
• Perault MC, Ladouch-Bures L, Dejean C, Delaunay C, Pouget Abadie JF, Vandel B: Rhabdomyolyse associée à la prise de pravastatine. Thérapie 1993, 48: 483-501
• Pfeffer MA, Sacks FM, Moyé LA, Brown L, Rouleau JL, Hartley LH, Rouleau J, Grimm R, Sestier F, Wickemeyer W, Cole TG, Braunwald E: Cholesterol and recurrent events: a secondary prevention trial for normolipidemic patient. Am J Cardiol 1995, 76: 98C-106C
• Pierce LR, Wysowski DK, Gross TP: Myopathy and rhabdomyolysis associated with lovastatin-gemfribrozil combination therapy. JAMA 1990, 264(1): 71-75
• Pierno S, De Luca A, Tricarico D, Roselli A, Natuzzi F, Ferrannini E, Laico M, Conte Camerino D: Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers. J Pharmacol Exp Ther 1995, 275(3): 1490-1496
• Poot M, Esterbauer H, Rabinovitch PS, Hoehn H: Disturbance of cell proliferation by two model compounds of lipid peroxidation contradicts causative role in proliferative senescence. J Cell Physiol 1988a, 137: 421-429
• Poot M, Schindler D, Kubbies M, Hoehn H, Rabinovitch PS: Bromodeoxyuridine amplifies the inhibitory effect of oxygen on cell proliferation. Cytometry 1988b, 9(4): 332-338
• Poot M, Verkerk A, Koster JF, Esterbauer H, Jongkind JF: Influence of cumene hydroperoxide and 4-hydroxynonenal on the glutathione metabolism during in vitro ageing of human skin fibroblasts. Eur J Biochem 1987, 162: 287-291
• Poot M, Verkerk A, Koster JF, Esterbauer H, Jongkind JF: Reversible inhibition of DNA and protein synthesis by cumene hydroperoxide and 4-hydroxynonenal. Mech Age Develop 1988c, 43: 1-9
• Pré J: Radicaux libres et peroxydation lipidique: I. Aspects biologiques généraux Sem Hôp Paris 1992, 68(41): 1430-1437
• Prendergast BD, George CF: Drug-induced rhabdomyolysis-mechanisms and management. Postgrad Med J 1993, 69: 333-336
• Pryor WA, Porter NA: Suggested mechanisms for the production of 4-hydroxy-2-nonenal from the autooxidation of polyunsaturated fatty acids. Free Rad Res Commun 1990, 8: 541-543
• Quion JAV, Jones PH: Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet 1994, 27(2): 94-103
• Rao PW, Robison WG, Bettelheim F, Lin LR, Reddy VN, Zigler JC: Role of small GTP-binding proteins in lovastatin-induced cataracts. Invest Ophthalmol Vis Sci 1997, 38: 2313-2321
• Rauchová H, Drahota Z, Lenaz G: Function of coenzyme Q in the cell: some biochemical and physiological properties. Physiol Res 1995, 44: 209-216
• Reahal S, Wrigglesworth J: Tissue concentrations of coenzyme Q₁₀ in the rat following its oral and intraperitoneal administration. Drug Metab Dispos 1992, 20(3): 423-427
• Reihnér E, Rudling M, Stahlberg D, Berglund L, Ewert HS, Björkhem I, Einarsson K, Angelin B: Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. NEJM 1990, 323: 224-228
• Reijneveld JC, Kott RW, Bredman JJ, Joles JA, Bär PR: Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats. Pediatr Res 1996, 39(6): 1028-1035
• Reimer KA, Murry CE, Richard VJ: The role of neutrophils and free radicals in the ischemic-reperfused heart: Why the confusion and controversy. J Mol Cell Cardiol 1989, 21: 1225-1239
• Rice-Evans C, Burdon R: Free radical-lipid interactions and their pathological consequences. Prog Lipid Res 1993, 32(1): 71-110
• Rifkind M: Lipid Research Clinics Program: The lipid research clinics coronary primary prevention trial results. JAMA 1984, 251: 351-364
• Rijke de YB, Bredie SJH, Demacker PNM, Vogelaar JM, Hak-Lemmers HLM, Stalenhoef AFH: The redox status of coenzyme Q₁₀ in total LDL as an indicator of in vivo oxidative modification: Studies on subjects with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1997, 17(1): 127-133
• Roberts WC: Effects of lipid lowering on coronary plaques and coronary events. AM J Cardiol 1997, 80(8): 8H-9H
• Roche Posicor warning against concomitant use with some statins added to labeling; Bristol's Pravachol and Novartis' Lescol are preferred, Roche says. 1997c, 22.12, 59(51): 6-7
• Romagnoli A, Oradei A, Destito C, Iacocagni A, Marin AW, Littarru GP: Protective role in vivo of coenzyme Q₁₀ during reperfusion of ischemic limbs. Molec Aspects Med 1994, 15(suppl): S177-S185
• Romero FJ, Roma J: Careful consideration of the effects induced by glutathione depletion in rat liver and heart. The involvement of cytosolic and mitochondrial glutathione pools. Chem Biol Interactions 1989, 70: 29-37
• Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction (see comments). JAMA 1998, 279(20): 1643-1650
• Ross H: The pathogenesis of atheroslerosis a perspective for the 1990s. Nature 1993, 362: 801-809
• Rossi MA, Garramone A, Dianzani MU: Stimulation of phospholipase C activity by 4-hydroxynonenal: Influence of GTP and calcium concentration. Int J Tiss Res 1988, 10: 321-325
• Rossi E, Lombardo A, Testa M, Lippa S, Oradei A, Littarru GP, Lucente M, Coppola E, Manzoli U: Coenzyme Q₁₀ in ischemic cardiopathy. pp. 321-326 in: Folkers K, Littaru GP, Yamagami T (eds): Biomedical and Clinical Aspects of Coenzyme Q. Elsevier Publishers 1991
• Rousseau G, Des Rosiers C, Varin F: A comparison of the effects of lovastatin and pravastatin on ubiquinone tissue levels in rats. Curr Ther Res 1998, 59(9): 666-679
• Rousseau G, Varin F: Determination of ubiquinone-9 and 10 levels in rat tissues and blood by high performance liquid chromatography with ultraviolet detection. J Chromatogr Sci 1998, 36(5): 247-252
• Rousseau G, Véronneau M, Des Rosiers C, Varin F: Effects of lovastatin and pravastatin on ubiquinone and 4-hydroxynonenal tissue levels in the hypercholesterolemic hamster. Cur Thera Res 1999, 60(2): 87-104
• Ruef J, Rao GN, Li F, Bode C, Patterson C, Bhatnagar A, Runge MS: Induction of rat aortic smooth muscle cell growth by the lipid peroxidation product 4-hydroxy-2-nonenal. Circulation 1998, 97(11): 1071-1078
• Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. NEJM 1996, 335(14): 1001-1009
• Sahnoun Z, Jamoussi K, Zeghal KM: Radicaux libres et anti-oxydants: physiologie, pathologie humaine et aspects thérapeutiques. Thérapie 1997, 52(4): 251-270
• Salonen R, Nyyssönen K, Porkkala-Sarataho E, Salonen JT: The Kuopio atherosclerosis prevention study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol 1995, 76: 34C-39C
• Sanma H, Yamafah, Yamano Y, Tanaka M, Tajima T, Kanazawa T, Hori S, Nakazawa H, Yoshino H, Miyamori R, Kojima M, Nakamura Y: Transfer of coenzyme Q₁₀ to the myocardium and its protective effect on ischemic myocardium in beagles. Biomedical Aspects of Coenzyme Q 1986, 5: 99-110
• Satoh K, Ichihara K: Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischemic rat hearts. Eur J Pharmacol 1995, 292: 271-275
• Sattler W, Kostner GM, Waeg G, Esterbauer H: Oxidation of lipoprotein Lp(a). A comparison with low-density lipoproteins. Biochim Biophys Acta 1991, 88: 1646-1650
• Schauenstein E: Effects of low concentrations of aldehydes on tumor cells and tumor growth, pp 159-171 in: McBrien DCH, Slater TF (eds): Free radicals, lipid peroxidation and cancer. Academic Press, New York 1982
• Schauenstein E, Esterbauer H: Formation and properties of reactive aldehydes, pp 225-244 in: Submolecular Biology and Cancer, Ciba Foundation Series 67. Excerpta Medica, Amsterdam 1979
• Schauenstein E, Esterbauer H, Zollner H: Aldehydes in biological systems: Their natural occurrence and biological activities. Pion Ltd, London 1977
• Schauenstein E, Taufer M, Esterbauer H, Kylianek A, Seelich Th: The reaction of protein-SH-groups with 4-hydroxy-pentenal. Monatsh Chem 1971, 102: 517-529
• Schaur RJ, Zollner H, Esterbauer H: Biological effects of aldehydes with particular attention to 4-hydroxynonenal and malonaldehyde, pp 141-163 in: Vigo-Pelfrey C (ed): Membrane lipid oxidation, vol 1. CRC Press, Boca Raton, Florida 1990
• Schnurr K, Hellwing M, Seidemann B, Jungblut P, Kühn H, Rapoport SM, Schewe T: Oxygenation of biomembranes by mammalian lipoxygenases: the role of ubiquinone. Free Rad Biol Med 1996, 20(1): 11-21
• Scholz RW, Minicucci LA, Reddy CC: Effects of vitamin E and selenium on antioxidant defense in rat heart. Biochem Mol Biol Int 1997, 42(5): 997-1006
• Schöneich C, Asmus K-D, Dillinger U, von Bruchhausen F: Thiyl radical attack on polyunsaturated fatty acids: a possible route to lipid peroxidation. Biochem Biophys Res Commun 1989, 161(1): 113-120
• Schwartz CJ, Kelley JL, Nerem RM, Sprague EA, Rozek MM, Valente AJ, Edwards EH, Prasad ARS, Kerbacher JJ, Logan SA: Pathophysiology of the atherogenic process. Am J Cardiol 1989, 64(suppl): 23G-30G
• SCRIP Roche withdraws Posicor. 1998, 2342(06.10): 20
• Selley ML, McGuiness JA, Jenkin LA, Bartlett MR, Ardlie NG: Effects of a 4-hydroxy-2,3-trans-nonenal on platelet function. Thromb Haemost 1988, 59: 143-146
• Serajuddin ATM, Ranadive SA, Mahoney EM: Relative lipophilicities, solubilities and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin and simvastatin. J Pharm Sci 1991, 80(9): 830-834
• Shepherd J: The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in scottish men. Am J Cardiol 1995, 76: 113C-117C
• Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, West of Scotland Coronary Prevention Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. NEJM 1995, 333(20): 1301-1307
• Sherrill BC, Dietschy JM: Characterization of the sinusoidal transport process responsible for uptake of chylomicrons by the liver. J Biol Chem 1978, 253: 1859-1867
• Shimomura I, Bashmakov Y, Shimano H, Horton JD, Golstein JL, Brown MS: Cholesterol feeding reduces nuclear forms of sterol regulatory element binding proteins in hamster liver. Proc Natl Acad Sci (USA) 1997, 94(23): 12354-12359
• Shiomi M, Ito T, Tsukada T, Yata T, Watanabe Y, Tsujita Y, Fukami M, Fukushige J-I, Hosokawa T, Tamura A: Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arterioscler Thromb Vasc Biol 1995, 15: 1938-1944
• Siems WG, Grune T, Esterbauer H: 4-hydroxynonenal formation during ischemia and reperfusion of rat small intestine. Life Sci 1995, 57(8): 785-9
• Siems WG, Hapner SJ, van Kuijk FJGM: 4-hydroxynonenal inhibits Na⁺ -K⁺-ATPase. Free Rad Biol Med 1996, 20(2): 215-223
• Siems WG, Zollner H, Grune T, Esterbauer H: Metabolic fate of 4-hydroxynonenal in hepatocytes: 1,4-dihydroxynonene is not the main product. J Lipid Res 1997, 38(3): 612-622
• Sies H: Oxidative stress: oxidants and antioxidants. Physiological society symposium: impaired endothelial and smooth muscle cell function in oxidative stress. Experimental Physiology 1997, 82: 291-295
• Singer II, Kawka DW, Kazazis DM, Alberts AW, Chen JS, Huff JW, Ness GC: HMG-CoA reductase containing hepatocytes are distributed periportally in normal and mevinolin-treated rat livers. Proc Natl Acad Sci (USA) 1984, 81: 5556-5560
• Singh RB, Singh NK, Rastogi SS, Wander GS, Aslam M, Onouchi Z, Kummerow FA, Nangia S: Antioxidant effects of lovastatin and vitamin E on experimental atherosclerosis in rabbits. Cardiovasc Drugs Ther 1997, 11(4): 575-580
• Singhvi SM, Pan HY, Morrison RA, Willard DA: Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 1990, 29: 239-243
• Sirtori CR: Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Ther 1993, 60: 431-459
• Slyper AH: Low-density lipoprotein density and atherosclerosis. JAMA 1994, 272(4): 305-308
• Smith SC Jr: Review of recent clinical trials of lipid lowering in coronary artery disease. Am J Cardiol 1997, 80(B): 10H-13H
• Smith PF, Eydelloth RS, Grossman SJ, Stubbs RJ, Schwartz MS, Germerhausen JI, MacDonald JS: Myopathy associated with HMG-CoA reductase inhibitors (HMGRIs) and cyclosporin A: evaluation in a rat model. European Heart Journal 1992, 13 (suppl B): 2-6
• Smith PF, Eydelloth RS, Grossman SJ, Stubbs RJ, Schwartz MS, Germerhausen JI, Vyas KP, Kari PH, MacDonald JS: HMG-CoA reductase inhibitor-induced myopathy in the rat: Cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 1991, 257(3): 1225-1235
• Sonoda Y, Gotow T, Kuriyam M, Nakahara K, Arimura K, Osame M: Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors. Muscle & Nerve 1994, 17: 891-897
• Spach DH, Bauwens JE, Clark CD, Burke WG: Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 1991, 154(2): 213-215
• Spady DK, Dietschy JM: Sterol synthesis in vivo in 18 tissues of the squirrel monkey, guinea pig, rabbit, hamster, and rat. J Lipid Res 1983, 24: 303-315
• Spady DK, Woollet LA, Dietschy JM: Regulation of plasma LDL-cholesterol levels by dietary cholesterol and fatty acids. Annu Rev Nutr 1993, 13: 355-381
• Srivastava SK, Awasthi S, Wang L, Bhatnagar A, Awasthi YC, Ansari NH: Attenuation of 4-hydroxynonenal-induced cataractogenesis in rat lens by butylated hydroxytoluene. Curr Eye Res 1996, 715(7): 749-754
• Srivastava S, Chandra A, Ansari NH, Srivastava SK, Bhatnagar A: Identification of cardiac oxidoreductase(s) involved in the metabolism of the lipid peroxidation-derived aldehyde-4-hydroxynonenal. Biochem J 1998a, 329(3): 469-475
• Srivastava S, Chandra A, Wang L-F, Seifert WE Jr, DaGue BB, Ansari NH, Srivastava SK, Bhatnagar A: Metabolism of the lipid peroxidation product, 4-hydroxy-trans-2-nonenal, in isolated perfused rat heart. J Biol Chem 1998b, 273(18): 10893-10900
• Stamler J, Wentworth D, Neaton JD: Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? JAMA 1986, 256(20): 2823-2828
• Steinberg D: Antioxidants and atherosclerosis. Circulation 1991, 84(3): 1420-1425
• Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D: Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci (USA) 1984, 81: 3883-3887
• Stocker R, Bowry VW, Frei B: Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does a-tocopherol. Proc Natl Acad Sci (USA) 1991, 88: 1646-1650
• Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN: Bilirubin is an antioxidant of possible physiological importance. Science 1987, 235: 1043-1046
• Stohs SJ: The role of free radicals in toxicity and disease. J Basic Clin Physiol Pharmacol 1995, 6(3-4): 205-228
• Sugiyama Y, Ishikawa E, Odaka H, Miki N, Tawada H, Ikeda H: TMP-153, a novel ACAT inhibitor, inhibits cholesterol absorption and lowers plasma cholesterol in rats and hamsters. Atherosclerosis 1995, 113(1): 71-78
• Sviridova DD, Endo A, Pavlova MY, Repina VS, Smirnova VN: Comparison of the effect of six compactin-related compounds on cholesterol synthesis in five human cell types. Lipids 1990, 25: 685-690
• Takahashi T, Okamoto T, Mori K, Sayo H, Kishi T: Distribution of ubiquinone and ubiquinol homologues in rat tissues and subcellular fractions. Lipids 1993, (28): 803-809
• Takeshige K, Takayanagi R, Minakami S: Lipid peroxidation and the reduction of ADP-Fe3+ chelate by NADH-ubiquinone reductase preparation from bovine heart mitochondria. Biochem J 1980, 192 (3): 861-866
• Tall A, Swenson T, Hesler C, Granot E: Mechanisms of facilitated lipid transfer mediated by plasma lipid transfer proteins. New Compr Biochem 1987, 14: 277-297.
• Tato Rocha RE, Cardenas Viedma E, Herrero Huerta E: Selenium: the physiopathological and clinical implications. An Med Interna 1994, 11: 457-463
• Tertov VV, Sobenin IA, Kaplun VV, Orekhov AN: Antioxidant content in low density lipoprotein and lipoprotein oxidation in vivo and in vitro. Free Rad Res 1998 29(2): 165-173
• Tesfamariam B, Cohen RA: Role of superoxide anion and endothelium in vasoconstrictor action of prostaglandin endoperoxide. Am J Physiol 1992, 262: H1915-H1919
• Thelin A, Peterson E, Hutson JL, McCarthy AD, Ericsson J, Dallner G: Effect of squalestatin-1 on the biosynthesis of the mevalonate pathway lipids. Biochim Biophys Acta 1994, 1215: 245-249
• Thelin A, Schedin S, Dallner G: Half-life of ubiquinone-9 in rat tissues. FEBS Lett 1992, 313(2): 118-120
• Thomas SR, Neuzil J, Stocker R: Cosupplementation with coenzyme Q prevents the prooxidant effect of alpha-tocopherol and increases the resistance of LDL to transition metal-dependent oxidation initiation. Arterioscler Thromb Vasc Biol 1996, 16(5): 687-696
• Thomas SR, Neuzil J, Stocker R: Inhibition of LDL oxidation by ubiquinol-10. A protective mechanism for coenzyme Q in atherogenesis? Molec Aspects Med 1997, 18(suppl): S85-S103
• Tikkanen MJ, Nikkilä EA: Current pharmacologic treatment of elevated serum cholesterol. Circulation 1987, 76(3): 529-533
• Tobert JA: Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988, 62: 28J-34J
• Tomono Y, Hasegawa J, Seki T, Motegi K, Morishita N: Pharmacokinetic study of deuterium labelled coenzyme Q₁₀ in man. Int J Clin Pharmacol Ther Toxicol 1986, 24: 536-541
• Transon C, Leemann T, Dayer P: In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996, 50: 209-215
• Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. NEJM 1995, 332(8): 481-487
• Triscari J, O'Donnell D, Zinny M, Pan HY: Gastrointestinal absorption of pravastatin in healthy subjects. J Clin Pharmacol 1995, 35: 142-144
• Tsujita Y, Ikeda T, Serizawa N, Hishinuma A, Komai T: Pravastatin sodium: New clinical aspects and recent progress. Ann Rep Sankyo Res Lab 1997, 49: 1-61
• Tsujita Y, Kuroda M, Shimada Y, Tanzawa K, Arai M, Kaneko I, Tanaka M, Masuda H, Tarumi C, Watanabe Y, Fujii S: CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta 1986, 877: 50-60
• Tsujita Y, Watanabe Y: Pravastatin sodium: a novel cholesterol-lowering agent that inhibits HMG-CoA reductase. Cardiovasc Drug Rev 1989, 7(2): 110-126
• Turley SD, Daggy BP, Dietschy JM: Cholesterol-lowering action of psyllium mucilloid in the hamster: sites and possible mechanisms of action. Metabolism 1991, 40: 1063-1073
• Turley SD, Dietschy JM: Cholesterol metabolism and excretion. Chapter 28, pp. 467-492 in: Arias I, Popper H, Schachter D, Shafritz (eds): The liver: biology and pathobiology. Raven Press, NY 1982
• Turley SD, Dietschy JM: The metabolism and excretion of cholesterol by the liver, pp. 617-641, in: Arias IM, Jakoby WB, Popper H, Schachter D, Shafritz DA (eds): The liver: biology and pathobiology 2nd ed. Raven Press, NY 1988
• Turley SD, Spady DK, Dietschy JM: Alteration of the degree of biliary cholesterol saturation in the hamster and rat by manipulation of the pools of preformed and newly synthesized cholesterol. Gastroenterology 1983, 84: 253-264.
• Uchida K, Stadtman ER: Selective cleavage of thioether linkage in proteins modified with 4-hydroxynonenal. Proc Natl Acad Sci (USA) 1992, 89: 5611-5615
• Ullrich O, Grune T, Henke W, Esterbauer H, Siems WG: Identification of metabolic pathways of the lipid peroxidation product 4-hydroxynonenal by mitochondria isolated from rat kidney cortex. FEBS Lett 1994, 352 (1): 84-86
• Ullrich O, Henke W, Grune T, Siems WG: The effect of the lipid peroxidation product 4-hydroxynonenal and of its metabolite 4-hydroxynonenoic acid on respiration of rat kidney cortex mitochondria. Free Rad Res 1996a, 24 (6): 421-427
• Ullrich O, Siems W G, Lehmann K, Huser H, Ehrlich W, Grune T: Inhibition of poly(ADP ribose) formation by 4-hydroxynonenal in primary cultures of rabbit synovial fibroblasts. Biochem J 1996b, 315(Pt 3): 705-708
• Urban T, Hurbain I, Urban M, Clément A, Housset B: Oxydants et antioxydants. Effets biologiques et perspectives thérapeutiques. Ann Chir 1995, 49: 427-434
• Vaca CE, Wilhelm J, Hams-Ringdahl M: Interaction of lipid peroxidation products with DNA. A review. Mutation Res 1988, 195: 137-149
• Valenzuela A: The biological significance of malondialdehyde determination in the assessment of tissue oxidative stress. Lif Sci 1990, 48: 301-309
• Vandeplassche G, Thoné F, Borgers M: Cytochemical evidence of NADH-oxidase activity in the isolated working rabbit heart subjected to normothermic global ischemia. Histochem J 1990, 22: 11-17
• Villalba JM, Navarro F, Gómez-Díaz C, Arroyo A, Bello RI, Navas P: Role of cytochrome b5 reductase on the antioxidant function of coenzyme Q in the plasma membrane. Molec Aspects Med 1997, 18(suppl): S7-S13
• Vliet van AK, Nègre-Aminou P, van Thiel GCF, Bolhuis PA, Cohen LH: Action of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiproliferative effect in cultured myoblasts from human striated muscle. Biochem Pharmacol 1996, 52: 1387-1392
• Vliet van AK, van Thiel GCF, Holger Huisman R, Moshage H, Yap SH, Cohen LH: Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochim Biophys Acta 1995, 1254: 105-111
• Vries de ACJ, Vermeer MA, Bloemendal H, Cohen LH: Pravastatin and simvastatin differently inhibit cholesterol biosynthesis in human lens. Invest Ophthalmol Vis Sci 1993, 34; 377-387
• Waclawik AJ, Lindal S, Engel AG: Experimental lovastatin myopathy. J Neurophathol Exp Neurol 1993, 52: 542-549
• Wade C, Van Rij AM: In vivo lipid peroxidation in man as measured by the respiratory excretion of ethane, pentane, and other low molecular weight hydrocarbons. Anal Biochem 1985, 150: 1-7.
• Wajner M, Harkness RA: Distribution of xanthine dehydrogenase and oxidase activities in human and rabbit tissues. Biochim Biophys Acta 1989, 991: 79-84
• Wakabayashi H, Yamato Y, Nakajima M, Shimada K: Simultaneous determination of oxidized and reduced coenzyme Q and a-tocopherol in biological samples by high performance liquid chromatography with platinum catalyst reduction and electrochemical detection. Biol Pharm Bull 1994, 17(8): 997-1002
• Waldius G, Wahlberg G: Nicotinic acid in the treatment of hyperlipidemia. A Short Overview. 8th Int Symp Drugs Affect Lipid Metab 1985
• Wang RW, Kari PH, Lu AYH, Thomas PE, Guengerich FP, Vyas KP Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991, 290(2): 355-361
• Waters D, Higginson L, Gladstone P, Kimball B, LeMay M, Boccuzzi SJ, Lesperance J, CCAIT Study Group: Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian coronary atherosclerosis intervention trial. Circulation 1994, 89: 959-968
• Watts GF, Burke V: Lipid lowering trials in the primary and secondary prevention of coronary heart disease: new evidence, implications and outstanding issues. Curr Opin Lipidol 1996, 7: 341-355
• Wawra E, Zollner H, Schaur RJ, Tillian HM, Schauenstein E: The inhibitory effect of 4-hydroxynonenal on DNA-polymerases alpha and beta from rat liver and rapidly dividing Yoshida ascites hepatoma. Cell Biochem Funct 1986, 4: 31-36
• Weber C, Jakobsen TS, Mortensen SA, Paulsen G, Holmer G: Effect of dietary coenzyme Q₁₀ as an antioxidant in human plasma. Mol Aspects Med 1994, 15 (suppl): s97-s102
• Wefers H, Sies H: The protection by ascorbate and glutathione against microsomal lipid peroxidation is dependent on vitamin E. Eur J Biochem 1988, 174: 353-357
• Weiss H, Friedrich T, Hofhaus G, Preis D: The respiratory-chain NADH dehydrogenase (complex I) of mitochondria. Eur J Biochem 1991, 197: 563-576
• Weissberg PL, Clesham GJ, Bennett MR: Is vascular smooth muscle cell proliferation beneficial? Lancet 1996, 347: 305-307
• Westhuyzen van der DR, Fourie AM, Coetzee GA, Gevers W: The LDL receptor. Curr Opin Lipidol 1990, 1: 128-135
• Willis RA, Folkers K, Tucker JL, Ye C-Q, Xia L-J, Tamagawa H: Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci (USA) 1990, 87: 8928-8930
• Winkle van WB, Snuggs M, Miller JC, Buja LM: Cytoskeletal alterations in cultured cardiomyocytes following exposure to the lipid peroxidation product, 4-hydroxynonenal. Cell Motil Cytoskeleton 1994, 28(2): 119-134
• Winnefeld K, Schirrmeister W, Thiele R, Sperschneider H, Klinger G et al. Selenium and antioxydant status in various diseases. Med Klin 1995, 90(suppl): 7-9
• Witz G: Biological interactions of alpha, beta-unsaturated aldehydes. Free Rad Biol Med 1989, 7: 333-349
• Witz G, Lawrie NJ, Amoruso MA, Goldstein BD: Inhibition by reactive aldehydes of superoxide anion radical production from stimulated polymorphonuclear leucocytes and pulmonary alveolar macrophages. Effects on cellular sulfhydryl groups and NADPH oxidase activity. Biochem Pharmacol 1987, 36: 721-726
• Witz G, Lawrie NJ, Goldstein BD, Ryer-Powder J, Amoruso MA: Effects of alpha, beta-unsaturated aldehydes on macrophage and neutrophil membrane function, fluidity and sulfhydryl status. Basic Life Sci 1988, 49: 849-857
• Witztum JL: Drugs used in the treatment of hyperlipoproteinemias. Chapter 34, pp. 875-897 in: Goodman and Gillman, 9th edition 1996
• Woollett LA, Spady DK, Dietschy JM: Mechanisms by which saturated triacylglycerols elevate the plasma low density lipoprotein-cholesterol concentration in hamsters. Differential effects of fatty acid chain length. J Clin Invest 1989, 84: 119-128
• Xie C, Lovell MA, Markesbery WR: Glutathione transferase protects neuronal cultures against four hydroxynonenal toxicity. Free Rad Biol Med 1998, 25(8): 979-988
• Yamada N, Shames DM, Stoudemire JB, Havel RJ: Metabolism of lipoproteins containing apolipoprotein B-100 in blood plasma of rabbits: heterogeneity related to the presence of apolipoprotein. E Proc Natl Acad Sci 1986, 83: 3479-3483
• Yamashita S, Yamamoto Y: Simultaneous detection of ubiquinol and ubiquinone in human plasma as a marker of oxidative stress. Anal Biochem 1997, 250: 66-73
• Zeiher AM: Endothelial vasodilator dysfunction: pathogenetic link to myocardial ischaemia or epiphenomenon? Lancet 1996, 348: S10-S12
• Zhang Y, Åberg F, Appelkvist E-L, Dallner G, Ernster L: Uptake of dietary coenzyme Q supplement is limited in rats. J Nutr 1995, 125: 446-453
• Zhang Y, Turunen M, Appelkvist EL: Restricted uptake of dietary coenzyme Q is in contrast to the unrestricted uptake of alpha-tocopherol into rat organs and cells. J Nutr 1996, 126 (9): 2089-2097
• Ziegler K, Blumrich M, Hummelsiep S: The transporter for the HMG-CoA reductase inhibitor pravastatin is not present in HEP G2 cells: evidence for the nonidentity of the carrier for pravastatin and certain transport systems for BSP. Biochim Biophys Acta 1994, 1223: 195-201
• Ziegler K, Stünkel W: Tissue-selective action of pravastatin due to hepatocellular uptake via a sodium-independent bile acid transporter. Biochim Biophys Acta 1992, 1139: 203-209
• Zierz S, Von Wersebe O, Bleistein J, Jerusalem F: Exogenous coenzyme Q (CoQ) fails to increase CoQ in skeletal muscle of two patients with mitochondrial myopathies. J Neurol Sci 1990, 95: 283-290